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ABSTRACT OF THE DISSERTATION
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Natural Abundance and Stable Isotope Labeled Thiocholine
by
Meng Chen
Doctor of Philosophy in Chemistry
Washington University in St. Louis, 2010
Professor Richard W. Gross, Chairperson

The reversible covalent phosphorylation of cellular proteins is widely believed to be
the most important mechanism for the regulation of multiple signal transduction
pathways in cell growth, division, and death by acting as a molecular switch at multiple
nodes in metabolic networks. In this dissertation, first, a novel mass spectrometric
strategy is reported that exploited the unique chemical properties of thiocholine that was
introduced into protein phosphosites through alkaline β-elimination and Michael addition
(BEMA),

allowing the

specific

detection,

identification

and

quantitation

of

phosphorylated serine/threonine containing peptides. Through replacement of the
phosphate with thiocholine as the Michael donor, this strategy resulted in a marked
increase in ionization sensitivity during ESI accompanied by enhanced peptide sequence
coverage during CID. Moreover, the definitive localization of phosphorylated residues is
greatly facilitated through the generation of diagnostic triads of fragment ions resulting
from peptide bond cleavage and further neutral loss of either trimethylamine (-59 Da) or
thiocholine thiolate (-119 Da) during CID in tandem mass spectrometric analyses such as
MS2 and MS3. Synthesis of stable isotope labeled thiocholine enabled the quantitation of
ii

protein phosphorylation with high precision by ratiometric comparisons. The utility of
this approach was demonstrated in an intact cell system through identification of the
endogenous phosphorylation sites in iPLA2β during heterologous expression in Sf-9 cells.
A total of 12 unique phosphopeptides and 19 phosphorylation sites were identified with
the developed strategy whereas the conventional approach identified only five peptides
and six phosphorylation sites. Lastly, the BEMA strategy was applied to in vivo tissue
system for the quantitative analysis of the murine myocardial mitochondrial
phosphoproteome following cardiac ischemia. A total of 36 phosphopeptides from 35
mitochondrial proteins with 50 phosphosites (37 of which were previously unknown),
were identified.
Collectively, we have demonstrated β-elimination of phosphate and subsequent
Michael addition (BEMA) with natural abundance and stable isotope labeled thiocholine
is an effective strategy for in vivo quantitative phosphoproteomics of both cell-based and
tissue-based systems.
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CHAPTER

1

INTRODUCTION

Posttranslational modifications (PTMs) of proteins are covalent transformations of
terminal residues or side chains of the polypeptide backbone that occur after protein
synthesis from mRNA, encoding each protein’s primary sequence [1]. The chemical
repertoire of protein functional diversity is greatly expanded through the addition of
specific functional groups (e.g., phosphorylation, acetylation, glycosylation) that confer
novel chemical properties to the primary amino acid sequence encoded by the mRNA
transcribed

from DNA. These PTMs serve multiple functions to facilitate

enzyme-substrate recognition, catalytic efficiency, and the subcellular localization of the
protein and the cadre of associated proteins that allow adaptive responses to cellular
perturbations [2-5]. Currently, more than 200 different PTMs have been discovered located
at tens of thousands of individual sites; they greatly expand the chemical diversity encoded
by each organism’s genomic structure [6].
Protein phosphorylation is the addition of a phosphate group to the side chain of an
amino acid residue through esterification. This process is catalyzed by a class of enzyme,
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called protein kinases. Phosphorylation is typically a reversible post translational
modification because cells contain numerous phosphatases that can reversibly remove the
phosphate moiety [7]. Collectively, the reversible cycle of phosphorylation and
dephosphorylation is a central determinant of cellular metabolic flux through exploiting
the differential catalytic or regulatory properties of the modified entity. Phosphorylation
has historically been considered to be the most ubiquitous and important post translational
modification of proteins; phosphorylation facilitates multiple changes in cellular
regulation and signaling thereby promoting key chemical alterations that lead to effective
adaptive regulation. In the human genome, about 2% of the encoded proteins are dedicated
to maintaining the appropriate phosphorylation state of targeted proteins through the
actions of a wide array of protein kinases and phosphatases [8-9]. Moreover,
approximately 30% of all known proteins in cells are rapidly and reversibly
phosphorylated to various extents during pathophysiologic perturbations to facilitate
cellular adaptation [10-12].
Although phosphorylation has been demonstrated to occur on the hydroxyl group of
serine, threonine, tyrosine, the carboxylic moiety of aspartic acid and glutamic acid [13];
the thiol group of cystine [14] or on basic amino acid residues such as arginine, lysine and
histidine [15-16]; reversible phosphorylations on serine, threonine and tyrosine residues
are of the greatest importance and collectively account for almost 99% of the protein
phosphorylation in eukaryotic cells [17]. Variations in the phosphorylation state of proteins,
often accompanied by changes in their tertiary structures, lead to alterations in their
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enzymatic activities and provide essential clues to the molecular mechanisms mediating
cellular activation after receptor stimulation or cellular adaptations reflecting fluctuations
in the nutritional state, cellular environment and metabolic history of the cell [18]. The
reversible covalent phosphorylation of cellular proteins is widely believed to be the most
important mechanism for the regulation of multiple signal transduction pathways in cell
growth, division, and death by acting as a molecular on/off switch at multiple nodes in
metabolic networks [19-21].
Therefore, comprehensive protein-phosphorylation studies that identify the
phosphosites and the level of phosphorylation have been conducted, leading to the growth
of a new field termed “Phosphoproteomics”. More specifically, the total chemical
characterization of phosphoproteins includes the detection, identification and quantitation
of component phosphopeptides as well as the localization of the exact residues that are
phosphorylated and the patterns of phosphorylation that are manifest in each protein.
Historically, labeling of proteins with radioactive phosphate (32P) has typically been
recognized as one of the “gold standards” for the detection of phosphorylated proteins and
the identification of changes in protein phosphorylation. In this approach, 32P is introduced
into phosphoproteins to enable detection usually by scintillation counting or
autoradiography. This technique was first introduced by Rall and Sutherland in 1956 [22].
There are generally two categories of 32P radiolabeling: in vivo (within the living) and in
vitro (within the glass) involving different approaches. In living systems, the 32P labeled
orthophosphate is transported across cells and converted into [γ-32P]-ATP that serves as the
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phosphate donor. The radioactive 32P orthophosphate can be delivered either in cell culture
experiments (by inclusion into the media), through perfusion in isolated organ systems or
by introduction into live animals, and by other more specialized methods. Next,
radiolabeled phosphates are transferred to amino acid targets (typically hydroxyl) by
various endogenous protein kinases [23-24]. In contrast, in vitro systems require
[γ-32P]-ATP and the addition of exogenous protein kinases that are suitable for substrate
protein or peptides contained in the target systems [25]. In both cases, 32P labeled proteins
are typically separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) according to their electrophoretic mobilities, which are a function of their
respective molecular weights. Traditionally these radiolabeled phosphoproteins are fixed
in the gel prior to detection by autoradiography. Comparative quantitation of protein
phosphorylation is achievable through the ratiometric comparisons of protein mass and 32P
radioactivity as revealed by Cerenkov radioactivity counting of excised bands [26].
Radiolabeling is a very sensitive method in terms of the detection of phosphoproteins.
There are, however, several disadvantages associated with it. First, large amounts of 32P are
required to detect the phosphorylation of low abundance proteins owing to isotopic
dilution from endogenous unlabelled ATPs; second, the success of labeling depends on the
relative rate of phosphorylation and dephosphorylation as well as the incubation time; third,
phosphosite localization requires mutagenesis, currently making it extremely difficult for
phosphosite determination in individual proteins and rendering the large scale high
throughput analysis of the phosphoproteome through this approach an intractable problem
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[17, 27].
Fluorescence labeling is a sensitive nonradioactive alternative to

32

P radiolabeling

with a detection limit at the nanogram level [28]. The fluorophore, which is a functional
group that can absorb energy of a specific wavelength (absorption spectrum) and re-emit
the energy at a different but specific wavelength (emission spectrum) to identify a molecule
of interest that is either covalently [29] or non-covalently [30] introduced into
phosphoproteins. Fluorescence labeling has been traditionally coupled with SDS-PAGE
where proteins are separated, stained, detected and quantitated with fluorescence
spectroscopy [31].
Phosphoproteins can also be detected by using immunoblotting methods [32], which
employ high-quality antibodies derived specifically for phosphorylated serine, threonine
and tyrosine residues. This technique will be discussed later in the enrichment of
phosphopeptides.
The strategies discussed above only provide an indication of the presence of
phosphoproteins and not information on the specific location or the extent of
phosphorylation of specific residues at each phosphosite. In early studies, Edman
degradation was the classic technique to locate the site of the phosphorylated amino acid
residues and could yield semi-quantitative results when coupled with HPLC. This
technique of stepwise degradation was first introduced by Pehr Edman in 1950 [33] who
demonstrated that phenyl thiohydantoins (PTH) derived from amino acid could be used to
cleave sequentially amino acids from the N-terminus of a protein or peptide. The strategy
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was later named “Edman Degradation”, in his honor, and was used for decades to sequence
proteins and peptides. Under the mild alkaline conditions of this method, the N-terminus of
a peptide chain reacts with phenyl isothiocyanate (PITC) to form a phenylthiocarbamyl
(PTC) derivative. Next, the first peptide bond from the N-terminus is cleaved under acidic
conditions to give rise to a thiazolinone amino acid derivative. This thiazolinone derivative
is isolated and transformed into the more stable isomer 3-phenyl-2-thiohydantoin
(PTH)-amino acid derivative, which can be identified and quantitated by HPLC through
comparing its elution profile with that of the standard PTH-amino acid derivative. The
shortened peptide subsequently undergoes additional cycles of this series of reactions.
Thus, by the identification of each individual PTH-amino acid derivative, the sequence of
the peptide is established from the N-terminus. Further, phosphorylated serines, threonines
and tyrosines can be located within the peptides.
Even under favorable conditions, Edman degradation can sequence a polypeptide
chain that contains only 30 to 50 amino acids owing to the deteriorating overall yield after
each cycle of reactions. Thus, useful information typically can only be obtained for only
15-20 residues [34]. It also requires pure peptides or proteins for unambiguous localization
of each amino acid. Other limitations include modest sensitivity at the picomole level and
time-consuming reaction and analysis processes [17]. Although automation is achievable
through the development of automatic sequenators [35], many N-termini of proteins are
blocked, precluding Edman degradation of these residues.
Unlike the techniques mentioned above, mass spectrometry (MS) is a
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multi-dimensional technique that is extremely sensitive, amenable to high-throughput
analyses, and can integrate protein phosphorylation detection, localization and quantitation
in a single experiment. Accordingly, mass spectrometry has become the state-of-the-art
technology for global phosphoproteomics in large part owing to the rapid advances in the
development of instrumentation, bioinformatics platforms, and application paradigms that
have revolutionized the field of MS during the past decade.
For MS studies, typically three major steps are employed in the analysis of a sample:
1) The generation of the ions in the ion source; 2) The selection and separation of the ions
in the mass analyzer; 3) The detection and visualization of the ions by the ion detector that
is coupled with data acquisition and analysis programs.
In the ion source, energy is transferred to the sample molecules, facilitating the
molecules to escape from its original phase, either liquid or solid, into the gas phase.
Neutral sample molecules are turned into charged ions through different mechanisms, such
as protonation/deprotonation, electron rejection/capture or adduct formation, usually
involving gas-phase reactions during the ionization process. Ion sources fall into two main
categories, liquid-phase sources and solid-phase sources, based on the different phases of
the samples and their surrounding matrices.
Traditional ion sources include Electron Ionization (EI) [36-37], Chemical
Ionization (CI) [38], Fast Atom/Ion Bombardment (FAB) [39], Secondary Ion Mass
Spectrometry (SIMS) [40-41] and other derivatives of these processes. However, these
ion sources are not suitable for large biomolecules, such as proteins and peptides; because
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either insufficient energy is provided for sample vaporization or sublimation, or excessive
amounts of energy are applied that often result in extensive fragmentation and the loss of
information from the intact analytes of interest. The development of Electrospray
Ionization (ESI) [42] and Matrix-assisted Laser Desorption Ionization (MALDI) [43] has
revolutionized the analysis of a wide variety of molecules, which has been recognized
through the award of Nobel Prizes in Chemistry in 2002 to John Fenn and Koichi Tanaka.
During electrospray, a strong electric field is applied to the solvent-containing analytes of
interest; these are passed through a heated capillary and dispersed into gas phase to form a
charged fine aerosol. The organic solvents, such as methanol, isopropanol and acetonitrile
are quickly vaporized under inert gas, such as nitrogen, shrinking the sizes of droplets
which in turn increases the droplet surface charge density and causes the droplets to divide
owing to a stronger coulombic force than the cohesion force. Subsequently, the droplets go
through shrinking cycles, and gas-phase ions are eventually formed either through
desorption from the charged droplet surface [44] or until the droplet contains a single
charged analyte molecule [45]. During the ionization process in MALDI, pulses of intense
laser are shot onto a thin solid mixture of matrix molecules and analytes. These matrix
molecules, such as alpha-cyano-4-hydroxycinnamic acid (α-CHCA), sinapic acid (SA) and
2,5-dihydroxy benzoic acid (2,5-DHB), strongly absorb laser wavelengths and transfer
the energy absorbed from the laser shot to the analytes, causing the sublimation of matrix
molecules and the formation of a matrix plume where analyte molecules are ionized
through gas-phase proton transfer [46].
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After the ions are formed, they are transferred to the mass analyzer and separated
according to their mass-to-charge ratio (m/z) through different schemes. A magnetic sector
analyzer separates ions according to their respective momentums [47]; a quadruple
analyzer determines m/z according to ion stability path [48]; kinetic energy is measured
and differences are compensated by using an electrostatic sector analyzer [49]; a
time-of-flight (TOF) analyzer measures ion flight time (i.e., velocity) [50]; whereas a
quadruple ion trap [51], a Fourier transform-ion cyclotron resonance (FT-ICR) [52] and an
Orbitrap analyzer all rely on ion orbital frequencies and restoring potentials to determine
m/z [53]. Different mass analyzers can be coupled together to form hybrid instruments that
access the advantages of each individual analyzer, such as accurate mass analyses that are
routinely performed today using time-of-flight (TOF), Fourier transform ion cyclotron
(FT-ICR) and Orbitrap mass analyzers.
Another important function of coupled or hybrid instrumentation is to perform
tandem mass spectrometry (MS/MS, or MS2) on the ions of interest. The first step is to
obtain the information regarding the ions of interest through scanning with one mass
analyzer. Then an ion of interest (precursor ion) is selected by the first mass analyzer,
fragmented through gas-phase collisions with air or other inert gases in the collision cell,
which may also be a mass analyzer [54]. The fragment ions, or product ions, resulting from
the collision are subsequently analyzed by a second mass analyzer to reveal the structural
information of the analyte [55]. Ion trap analyzers are capable of performing tandem mass
spectrometric analyses independently, in time rather than in space, but their mass accuracy
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is limited especially by current technology [51].
To achieve better sensitivity when analyzing complex samples, MS is often coupled
with a separation technique, such as gas chromatography (GC) [56-57], high-performance
liquid chromatography (HPLC) [58] or capillary electrophoresis (CE) [59-60]. The
analytes are separated according to their different physical or chemical properties, and they
are either directly introduced into the mass spectrometer for analysis (on-line) or collected
and analyzed off-line.
Despite possessing advantages such as high sensitivity, high-throughput, high
tolerance of sample impurity and the ability to carry out the detection, identification,
localization and quantitation of phosphorylation sites simultaneously, mass spectrometric
procedures for the analysis of protein phosphorylation still have considerable limitations
owing to the intrinsic chemical properties of phosphorylated proteins. Peptides containing
phosphorylated serine/threonine (pS/pT) residues rapidly undergo neutral loss of
phosphoric

acid

(H3PO4)

through

cyclo-elimination

occurring

in

low-energy

collision-induced dissociation (CID); this reaction leads to loss of sequence coverage [61].
In addition, typical signaling proteins undergo reversible phosphorylation and are often
present in extremely low abundance. Furthermore, protein phosphorylation patterns, which
are of great biological significance, are heterogeneous and extremely difficult to determine.
Phosphorylated peptides generally have poor ionization efficiencies in the positive ion
mode due to the acidity of the phosphate group and ion suppression [17]. Therefore,
various methods are available to improve the analysis of the phosphoproteome from
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different perspectives.
Precursor-ion scanning utilizes the signature fragment ion of phosphate (PO3-, m/z =
79) from phosphopeptides during CID in the negative-ion mode [62-63]. This scanning
mode is highly effective for the identification of phosphopeptides. Nonetheless, the exact
location of the phosphorylated residue cannot be determined in these studies using the
negative-ion mode. Phosphosite localization usually requires a separate sample run under
acidic conditions in the more sensitive positive-ion mode. Another scanning mode that
takes advantage of the neutral loss of phosphoric acid is neutral-loss triggered in an MS3
experiment with an ion trap mass analyzer [64-65]. As mentioned above, the neutral loss of
H3PO4 will prevent the cleavage of the peptide bond in CID. However, data-dependent
MS3 was employed to analyze further fragment ions that are 98 Da less than the precursor
ions to reveal sequence information. Multistage activation utilizes a similar approach to
induce the fragmentation of precursor ions and the target fragment ions resulting from the
neutral loss of phosphoric acid in one single experiment [66-67]. This effectively combines
product-ion spectra from MS2 and MS3 into a single spectrum. The actual utility of both
neutral-loss triggered MS3 and multistage activation in large-scale phosphoproteome
analysis is debatable compared to utilizing a high-mass accuracy instrument employing
conventional strategies [68].
The above-mentioned neutral loss of H3PO4 is associated with commonly employed
collision induced dissociation (CID). In CID, peptide fragmentation depends on the
protonation of the peptide-bond nitrogen and an increase in vibrational energy that a
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peptide gains through the collision with inert gas (e.g., helium, argon) that allows it to
traverse the energy barrier required for the cleavage of a peptide bond. Thus, the
fragmentation behavior of a peptide in CID depends on its specific sequence and the
posttranslational modifications (PTMs) [61]. Other fragmentation methods can circumvent
the unwanted neutral loss of phosphate; these include electron-capture dissociation (ECD)
[69] and electron-transfer dissociation (ETD) [61]. In ECD, proteins and peptides that are
bearing multiple positive charges from the protonation process during electrospray react
with electrons in a Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer
causing fragmentation of the peptide backbone in a series of radical-induced reactions that
are independent of the nature of the amino acid residues, leaving the PTMs intact [70-71].
However, the utility of ECD is somewhat limited because that it can only be coupled with
FT-ICR, which is more expensive to build and maintain than any other mass spectrometer
since the storage of the electron requires static electric and magnetic fields [72]. On the
other hand, in the recently developed method of ETD, an electron is transferred to a peptide
through the gas-phase reaction between the peptide molecule and an anionic compound
that serves as an electron carrier. The electron carrier usually has a very low
electron-affinity; it is often an anion that can easily lose the extra electron; an example
neutral is anthracene. Similar to ECD, ETD leads to the generation of c and z fragment ions
instead of the b and y ions that form in CID, and the phosphate group on the amino acid
residue remains intact [73-74]. ETD can be coupled with routine mass spectrometers such
as quadruple ion trap and linear ion trap, expanding its utility in phosphoproteomics.
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However, doubly charged peptides generally have poorer sequence coverage than do
high-charge peptides in ETD because they undergo non-dissociative electron transfer [75]
and, thus, must usually be coupled with traditional CID for improved results [76-77].
Because the abundance of phosphoproteins is low, efforts have been focused on the
development of enrichment strategies. Immunoblotting is a very sensitive method for the
detection of phosphoproteins as discussed earlier. Similarly, antibodies have been utilized
to enrich phosphorylated proteins and peptides found in a complex mixture. Although
antibodies are available specifically for phosphorylated serines, threonines and tyrosines
[78-80], those for phosphorylated serines and threonines are less effective than those for
phosphorylated tyrosines. Numerous studies on phosphorylated tyrosine residues involved
in signal transduction pathways show, through enrichment by immunoprecipitation and
subsequent analysis, improved signal to noise ratio. [81-82].
Immobilized metal affinity chromatography (IMAC) is used to enrich
phosphopeptides based on the affinity interaction between the phosphate group and metal
ions (e.g., Fe3+, Ga3+) that are immobilized on a stationary phase [83-84]. For improved
selectivity of IMAC, methyl esterification was adapted to reduce the undesirable binding
of acidic/electron rich residues [85]. However, the identification of phosphopeptides is
complicated by incomplete and or nonspecific methyl esterification [86]. Other enrichment
strategies, such as utilizing titanium dioxide (TiO2) [87] and zirconium dioxide (ZrO2) [88]
have shown better specificity towards phosphopeptides. Titanium dioxide is the most
commonly employed enrichment resin. This strategy is based on the affinity between the
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phosphate group and titanium dioxide through formation of a bridging bidentate surface
complex [89]. It can be used offline in the form of a micro-column [86], or coupled with
traditional HPLC columns in an online multidimensional liquid chromatography setting
[90]. Strong cation exchange chromatography (SCX) is another widely used enrichment
method that does not have specificity for phosphopeptides compared to other enrichment
strategies but can considerably reduce sample complexity. The reduction in sample
complexity results from the early elution of phosphorylated peptides owing to their low
charge state in acidic conditions. The majority of the tryptic peptides are doubly (+2) or
triply (+3) charged under these conditions and, thus, elute later than their phosphopeptide
counterparts. Strong cation exchange chromatography is usually utilized in tandem with
other enrichment or separation techniques, such as TiO2 or reverse-phase (RP)
chromatography either offline [91] or online [92].
Because phosphorylated tyrosines comprise only approximately 0.1% of the total
phosphorylation present in proteins and can be effectively enriched through
immunoprecipitation with commercially available antibodies as mentioned above, focus
has been centered on improved strategies for analysis of phosphorylated serines (~90%)
and threonines (~10%). Chemically replacing the phosphate on serine or threonine with
other functional groups via alkaline induced β-elimination and subsequent Michael
Addition (BEMA) is one such approach that was first introduced by Myers et al in 1986
[93]. Phosphorylated tyrosines are stable under alkaline conditions becuase the β-proton is
on the benzene moiety and is not readily eliminated [27]. The major limitation of this
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strategy is the non-specific β-elimination reaction that occurs on other residues besides
phosphorylated serine and threonine. Residues such as alkylated cysteines, O-glycosylated
serines and threonines as well as non-phosphorylated serines and threonines undergo
β-elimination and generate the same product residues of dehydroalanine or
β-methyldehydroalanine as phosphoserine and phosphothreonine, respectively, and,
therefore, non-specific loss cannot be differentiated from a genuine phosphosite [94]. This
was solved by the introduction of catalytic specificity through the use of a bivalent metal
hydroxide. More specifically, through employing barium hydroxide (Ba(OH)2) as the
catalyst for the β-elimination of the phosphate group, β-elimination of alkylated cysteines
or O-glycosylated serines and threonines occur two orders of magnitude more slowly than
β-elimination from pS/pT and non-phosphorylated serine and threonine residues are
unaffected [95].
The BEMA strategy not only eliminates the unfavorable neutral loss of H3PO4 but
also increases the ionization ability of the phosphorylated peptides by removing the acidic
phosphoric acid side chain. Furthermore, various functional groups can be incorporated
into the phosphopeptides to act as molecular handles to achieve different goals. Affinity
pairs can be applied in the BEMA reaction, in which one is attached to the side chain (e.g.
biotin) while the other serves as stationary phase for the enrichment, such as avidin [96].
Alternatively, a perfluorinated tag and fluorous solid phase extraction columns can be
employed [97]. The functional group could also serve as a resource for characteristic
fragment

ions

in

tandem

mass

spectrometry
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analysis,

such

as

using

2-dimethylamino-ethanethiol as the Michael donor followed by hydrogen peroxide
oxidation to generate a thioester ethanesulfoxide derivative that generates a characteristic
fragment ion in the low-energy CID mode [98]. The utilization of cysteamine as the
nucleophile in BEMA can even convert the formally phosphorylated peptides into a
substrate of trypsin so that phosphorylation information is obtained at the time of
enzymatic proteolysis [99]. The utility of the BEMA strategy is further extended through
stable isotope labeled Michael donors, which together with their natural abundance
counterparts, enable comparative quantitative phosphoproteome analysis [100-102].
Stable isotope labeling with amino acids in cell culture (SILAC) is a common
strategy for comparative quantitative phosphoproteomics [103-105]. SILAC utilizes cells
grown in separate media conditions to label cellular proteins with light (natural abundance)
and heavy (isotope labeled) amino acids. Then the proteins from two different cell culture
conditions are mixed together at a normalized total protein content, trypsinized, separated
using HPLC and analyzed by mass spectrometry. The same phosphopeptides labeled with
light and heavy amino acids will elute from the HPLC column at the same time, and their
peak intensity ratio indicates the different extents of phosphorylation of this peptide in two
different cell states. Thus, the quantitation information is obtained at the molecular ion
level. However, the obvious limitation of SILAC is that it cannot be used to conduct
quantitative phosphoproteome analysis in tissue samples; these analyses are more likely to
reveal the biological significance of changes in protein phosphorylation in living animals.
Isobaric tags for relative and absolute quantitation (iTRAQ) is also a useful labeling
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technique for multiplexed quantitative phosphoproteomics [106-107]. Peptides digested
from the proteins of up to four different biological states are modified with different
isobaric tags at their N-termini. The same phosphopeptides from different states are
indistinguishable from one another in a molecular ion scan because they possess the same
m/z. However, during the tandem mass spectrometric analysis, the isobaric tags can
produce different reporter fragment ions in the low-mass region (m/z = 114-117). Therefore,
by comparing the relative abundances of the reporter ions, the phosphorylation change of
this peptide is revealed. iTRAQ can be used in the analysis of tissue samples because the
modifications are at peptide level. However, given that the quantitation is achieved at the
MS2 level, the sensitivity of this strategy is limited and could lead to large run-to-run
deviations and, thus, poor reproducibility.
With the insight to develop a BEMA based technology with a molecular handle that
possesses strong nucleophilicity, the ability to increase peptide ionization efficiency and a
unique structure that would produce characteristic fragment in tandem mass spectrometric
analysis, we demonstrate in the first part of this thesis, the development of a novel strategy
employing the unique chemical properties of the quaternary amine present in thiocholine
(2-mercapto-N,N,N-trimethyl-ethanaminium) in conjunction with alkaline β-elimination
and Michael addition (BEMA) reactions for the specific detection, identification and
quantitation of phosphorylated serine/threonine-containing peptides. Through replacement
of the phosphate with thiocholine, the negative charge on the phosphopeptide is switched
to a quaternary amine containing a permanent positive charge (Scheme 1.1). This strategy
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results in a markedly increased ionization sensitivity during ESI (with a sub-500 amol/µL
detection limit) accompanied by the enhanced production of informative peptidic fragment
ions during CID that affords increased sequence coverage. Moreover, the definitive
localization of phosphorylated residues is greatly facilitated through the generation of
diagnostic triads of fragmentation ions resulting from peptide bond cleavage and further
neutral loss of either trimethylamine (-59 Da) or thiocholine thiolate (-119Da) during CID
in MS2 and MS3 experiments (Scheme 1.2). Synthesis of stable isotope labeled thiocholine
enabled the quantitation of protein phosphorylation with high precision using ratiometric
comparisons of heavy and light thiocholine (Scheme 1.3).
The second part of this thesis describes the application of the developed BEMA
strategy for the identification of endogenous phosphorylation sites of the hexahistidine
tagged calcium-independent phospholipase A2β (iPLA2β) heterologously expressed in Sf9
cells. In parallel, traditional direct analysis of phosphopeptides with data-dependent
acquisition MS2 and neutral loss of phosphoric acid triggered MS3 was also used to analyze
iPLA2β phosphorylation. The two methods were compared and evaluated to show that the
BEMA strategy was substantially more effective in the identification of phosphopeptides
and localization of phosphosites with better ion scores as well as higher sequence coverage
than the traditional direct analysis. 3-D structure modeling of the iPLA2β protein was also
generated with I-TASSER [108-110] to reveal the spacial relations between the
phosphorylated residues and the catalytic site of the enzyme.
The third part of this thesis identifies the quantitative alterations in the myocardial
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mitochondrial phosphoproteome induced by cardiac ischemia was studied by using mass
spectrometry with the developed strategy, β-elimination of phosphate and subsequent
Michael addition (BEMA), with natural abundance thiocholine and stable isotope labeled
thiocholine. In addition to increased ionization efficiency, sensitivity and improved
identification through characteristic diagnostic triads in MS2 and MS3 levels enabled by
BEMA strategy, a highly selective phosphopeptide enrichment technique using titanium
dioxide resin (TiO2) was incorporated prior to the BEMA reactions to reduce sample
complexity and improve reaction yields for phosphopeptides [87]. The MASCOT search
engine was used to conduct all database searches [111]. The results generated by MASCOT
were re-scored by Percolator [112-113], a program that utilizes a semi-supervised machine
learning algorithm called support vector machine (SVM) to compare true and false
positives, for improved phosphopeptides identification.
In this study, the phosphoproteome of mitochondria obtained from isolated
Langendorff-perfused mouse hearts that underwent global ischemia was investigated. The
comparative quantitation of phosphorylation changes as a result of ischemia was achieved
by comparing the phosphopeptides modified by heavy thiocholine from mitochondria of
ischemic hearts to those modified by light thiocholine from control hearts that were
perfused normally. We identified 141 phosphopeptides from 133 unique proteins with 227
phosphorylated sites from 6 independent biological replicates generated from 24 perfused
mouse hearts (12 control-perfused, 12 global ischemic), including 36 phosphopeptides
from 35 mitochondrial proteins with 50 phosphosites and 37 new mitochondrial
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phosphosites that have not been reported previously. This study has demonstrated that
β-elimination of phosphate and subsequent Michael addition (BEMA) using light and
heavy thiocholine together with a TiO2 phosphopeptide enrichment method and a
Percolator re-scoring algorithm represents a very effective mass-spectrometry based
strategy for comparative quantitative phosphoproteome analysis of in vivo tissue-based
systems.
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Schemes

Scheme 1.1 Chemical modification of phosphoserine and phosphothreonine containing
peptides via β-elimination in the presence of Ba(OH)2 and Michael Addition with
thiocholine as the Michael donor.
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Scheme 1.2 Collision induced dissociation (CID) resulting in the neutral loss of either (A)
trimethylamine (m = 59 Da) or (B) the thiocholine thiolate (m = 119 Da) from the
thiocholine peptide adduct.
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Scheme 1.3
A. Synthesis of thiocholine through acidic hydrolysis of S-acetylthiocholine (72% yield).

B. Synthesis of thiocholine-13C,d3. The thiol group of 2-(dimethylamino)ethanethiol was
protected by thioesterification with acetic anhydride prior to the addition of methyl-13C,d3.
The final product was obtained through acidic hydrolysis (50% yield).
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CHAPTER 2

Facile Identification and Quantitation of Protein Phosphorylation via β-Elimination
and Michael Addition with Natural Abundance and Stable Isotope Labeled
Thiocholine

2.1 Abstract

Herein, we employ the unique chemical properties of the quaternary amine present
in thiocholine (2-mercapto-N,N,N-trimethyl-ethanaminium) in conjunction with alkaline
β-elimination and Michael addition (BEMA) reactions for the specific detection,
identification and quantitation of phosphorylated serine/threonine-containing peptides.
Through replacement of the phosphate with thiocholine, the negative charge on the
phosphopeptide is switched to a quaternary amine containing a permanent positive charge.
This strategy resulted in a marked increase in ionization sensitivity during ESI (sub-500
amol/μL detection limit) accompanied by a markedly enhanced production of informative
peptidic fragment ions during CID that dramatically increase sequence coverage.
Moreover, the definitive localization of phosphorylated residues is greatly facilitated
through the generation of diagnostic triads of fragmentation ions resulting from peptide
bond cleavage and further neutral loss of either trimethylamine (-59 Da) or thiocholine
thiolate (-119 Da) during CID in MS2 and MS3experiments. Synthesis of stable isotope
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labeled thiocholine enabled the quantitation of protein phosphorylation with high
precision by ratiometric comparisons using heavy and light thiocholine. Collectively, this
study demonstrates a sensitive and efficient strategy for mapping of phosphopeptides by
BEMA using thiocholine through the production of a diagnostic repertoire of unique
fragment ions during LC-MS2/MS3 analyses, facilitating phosphosite identification and
quantitative phosphoproteomics.
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2.2 Introduction

In the human genome, about 2% of the encoded proteins are dedicated to
maintaining the appropriate phosphorylation state of targeted proteins through the actions
of a wide variety of protein kinases and phosphatases [1-2]. Moreover, approximately 30%
of all known proteins in cells are rapidly and reversibly phosphorylated to various extents
during physiologic or pathophysiologic processes, making phosphorylation one of the
most common post-translational modifications (PTMs) of proteins [3]. Although
phosphorylation can occur on many amino acid residues (e.g., aspartic acid, glutamic acid,
arginine and etc), reversible phosphorylations of serine, threonine and tyrosine
collectively account for almost 99% of the protein phosphorylation in cells. The
reversible covalent phosphorylation of cellular proteins is widely believed to be the most
important mechanism for the regulation of multiple signal transduction pathways [4-6].
The intrinsic chemical properties of phosphorylated peptides render the detection,
identification of the phosphorylation sites, and quantitation of alterations in
phosphorylation state a challenging problem in proteomics [7-8]. Peptides containing
phosphorylated serine/threonine (pS/pT) rapidly undergo neutral loss of phosphoric acid
through cyclo-elimination during low-energy CID, and this leads to the loss of peptide
sequence coverage. Typical signaling proteins are present in extremely low abundance.
While the phosphorylation patterns of these signaling proteins are of great biological
significance; they are highly diversified and oftentimes extremely difficult to determine
owing to the presence of multiple S or T residues. Moreover, phosphorylated peptides
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generally have poor ionization efficiencies in the positive-ion mode owing to the acidity
of the phosphate group and ion suppression [9-12].
Complementary approaches have been developed to overcome these difficulties.
Enrichment using immobilized metal affinity chromatography (IMAC) after esterification
of carboxylates has been useful in many cases [13-15]. However, identification of
phosphopeptides is complicated by polydispersity generated by potentially incomplete
and nonspecific methyl esterification [16]. Other enrichment strategies, such as use of
titanium dioxide [17-18] and zirconium dioxide [19] have shown great efficiency, but
these approaches are still hindered by the intrinsic chemical properties of the phosphate
moiety that facilitates its neutral loss. The utility of electron transfer dissociation (ETD)
in phosphopeptide analysis is becoming increasingly appreciated [12]. ETD generates cand z-type ions in which the neutral loss of H3PO4 does not occur [20-21].
Finally, phosphorylated tyrosine comprises only about 0.1% of the total
phosphorylation in proteins, and its enrichment and analysis can be effectively achieved
through immunoprecipitation with high quality commercially available antibodies
[22-23]. Accordingly, analytic efforts have focused on identification and quantitation of
phosphorylated serine (~90%) and threonine (~10%) residues that account for the
overwhelming majority of phosphorylation in cells. Chemical replacement of the
phosphate on serine or threonine with other functional groups by β-elimination and
subsequent Michael addition (BEMA) was first introduced by Meyers et al. in 1986 [24].
Since then, this strategy has been widely studied and applied effectively with different
Michael donors in the enrichment, identification, quantitation of peptides containing
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phosphoserine and phosphothreonine [25-27]. In prior work, Steen et al. demonstrated
the efficacy of 2-dimethylamino-ethanethiol followed by hydrogen peroxide oxidation to
generate thioester ethanesulfoxide derivatives that produced informative fragment ions
during low-energy CID [28]. However, controlled oxidation with the generation of a
single predominant reaction product is not straightforward. With cysteamine as the
Michael donor, Knight et al. developed a strategy to cleave enzymatically proteins at
their phosphorylation sites [29]. Although information on the phosphorylated proteins can
be obtained through enzymatic proteolysis, lysine residues have to be quantitatively
blocked through additional chemical reactions to ensure the exclusive cleavage at
modification sites. During the development of our strategy, Li et al. used BEMA with
several nucleophiles including thiocholine for the detection of phosphopeptides by
Raman spectroscopy and mass spectrometry. However, prior mass spectrometric analyses
were limited to detection of molecular ions in full MS scans without exploring the unique
advantages of this strategy for covalent identification of specific phosphorylation sites
through the enhanced generation of informative fragment ions in either the MS2 or MS3
modes [30].
In this study, we report a novel strategy for specific detection, identification and
quantitation of pS/pT-containing peptides. Thiocholine is introduced into the peptide at
the phosphorylation site via high-yield Ba2+ catalyzed β-elimination of phosphate and
subsequent Michael addition (Scheme 1.1). Sample complexity is reduced through
reductive alkylation of cysteines and development of optimized BEMA conditions for pS
or pT individually. This charge-switch strategy with the thiocholine quaternary amine
37

results in a marked increase in ionization efficiency during ESI with detection levels in
the sub 500 amol/μL range. The increased endogenous positive charge also engenders
higher charge states of thiocholine-labeled tryptic peptides facilitating the production of
peptidic fragment ions resulting in increased sequence coverage. Furthermore,
phosphopeptide identification has been substantially improved by exploiting the facile
neutral loss of trimethylamine (59 Da) and the thiocholine thiolate (119 Da) from the
thiocholine adduct (Scheme 1.2). Thus, CID contains not only the b and y series of
peptidic fragment ions but, in addition, a diagnostic array of fragment ions during MS2
and MS3 analyses. Finally, through the synthesis and use of stable isotope labeled
thiocholine, quantitative analysis of alterations in the phosphorylation state of proteins
during cellular perturbations can be performed through ratiometric comparisons of
phosphopeptides containing stable isotope labeled thiocholine to those containing natural
abundance thiocholine.
.
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2.3 Materials and Methods

Materials
Phosphoprotein β-Casein and phosphopeptide FQpSEEQQQTEDELQDK were obtained
from Sigma-Aldrich (St. Louis, MO), phosphopeptide DHTGFLpTEYVATR was
obtained from BIOMOL (Plymouth Meeting, PA); POROS 20 R2 resin was purchased
from ABI (Foster City, CA); Slide-A-Lyzer MINI Dialysis Unit, 7K MWCO was
purchased from Pierce (Rockford, IL); Rapigest was purchased from Waters (Milford,
MA); Protein Kinase A and trypsin were purchased from Promega (Madison, MI);
α-cyano-4-hydroxycinnamic acid (α-CHCA) solution was obtained from Agilent (Santa
Clara, CA). All solvents for mass spectrometric analyses were obtained from Honeywell
Burdick&Jackson (Muskegon, MI). All other chemicals were obtained from
Sigma-Aldrich (St. Louis, MO)

Synthesis of Thiocholine Chloride and Thiocholine-13C,d3 Chloride
Thiocholine chloride was prepared as previously described by Moss et al. with minor
modifications [31]. Briefly, S-acetylthiocholine chloride, 1 g (5 mmol), was dissolved in
10 mL of nitrogen-purged Millipore-purified water, followed by addition of 3.5 mL
concentrated HCl to give a solution of 3 N HCl. The solution was heated to 80 °C under
nitrogen for 30 min and HCl was evaporated from the solution while drying under
vacuum. The dried product was then triturated with anhydrous diethyl ether (3~5 mL)
and absolute ethanol (3~5 mL). Additional anhydrous ether was added to precipitate the
39

product (10 mL) which was filtered and re-crystallized using hot anhydrous ethanol and
anhydrous diethyl ether (0.56g, 3.6 mmol).{ 1H NMR (D2O) δ 2.75-2.85 (m, 2H, CH2S),
3.0 (s, 9H, N(CH3)3), 3.35-3.45 (m, 2H, CH2N)}(Appendix A).
Thiocholine-13C,d3 chloride was prepared similarly to thiocholine chloride, except
that the precursor S-acetylthiocholine-(N,13C,d3) was synthesized according to Ouyang et
al. [32]. Briefly, 2.82 g (20 mmol) 2-(dimethylamino)ethanethiol hydrochloride and 2.82
mL (30 mmol) acetic anhydride were mixed and refluxed for 10 min. The mixture was
allowed to stand overnight and transferred to a mortar where the solid was triturated with
ethyl ether (3-5 mL), the precipitate (2.9 g, 20 mmol)) was resuspended in 5 mL acetone
and the pH was neutralized using NaHCO3. Next, 5 g (25 mmol) of iodomethane-13C,d3
was added and incubated at room temperature under nitrogen for 48 h. Subsequently,
thiocholine-13C,d3 chloride was obtained using the same hydrolysis method as that for the
naturally occurring isotope described above (1.6 g, 10 mmol). {1H NMR (D2O) δ
2.75-2.85 (m, 2H, CH2S), 2.97, 2.98 (d, 6H, N(CH3)2), 3.35-3.45 (m, 2H,
CH2N)} )}(Appendix B).
The free thiol concentrations of both light and heavy thiocholine were determined
using Ellman’s assay [51]. Briefly, 40 mg 5,5‘-dithiobis(2-nitrobenzoic acid) (DTNB)
was added in 0.1 M phosphate buffer (pH 8.0) 10 mL. 0.1 mL of this prepared solution
(Ellman’s reagent) was mixed with 2 mL of 0.1 M phosphate buffer (pH 8.0) containing
0.1 mg of EDTA in a cuvette. The absorbance of the resultant solution was measured at
412 nm. Next 6 μL of light or heavy thiocholine chloride solution at the concentration of
0.03mmol/5mL (by weight) was added directly to the same cuvette and was incubated at
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room temperature for 15 min. The absorbance of the resultant solution was measured at
412 nm. The concentration of free thiol in the cuvette was calculated using the equation
ΔA (net change of absorbance) = ε412nm x CSH, where ε412nm = 13.6 cm-1 mM-1. The results
indicated a 98% free thiol content in the prepared thiocholine samples. The overall
reaction yield for light thiocholine was 72% and 50% for heavy thiocholine chloride.

BEMA of Model Phosphopeptide FQpSEEQQQTEDELQDK with Thiocholine
The phosphopeptide FQpSEEQQQTEDELQDK was modified via BEMA with
thiocholine according to the method of Shokat et al. with minor modifications [29].
Lyophilized FQpSEEQQQTEDELQDK was suspended in water to make a 40 pmol/μL
stock solution. 12.5 μL of this stock solution was mixed with 9.5 μL DMSO and 3 μL
absolute ethanol followed by the addition of 12.5 μL of freshly prepared saturated
Ba(OH)2. The reaction was incubated at room temperature under nitrogen for 1 h with
gentle vortexing every 20 min. The final pH was 12~13. Next, 25 μL of 1 M thiocholine
solution freshly prepared in water was directly added to the reaction. The reaction
mixture was incubated at room temperature under nitrogen for 3 h at pH 8~9 and then
terminated by the addition of 5 μL of 10% TFA.

BEMA of Model Phosphopeptide DHTGFLpTEYVATR with Thiocholine
Lyophilized DHTGFLpTEYVATR was suspended in water to make a 40 pmol/μL stock
solution. 12.5 μL of this peptide stock solution was mixed with 9.5 μL DMSO and 3 μL
absolute ethanol followed by the addition of 12.5 μL freshly prepared saturated Ba(OH)2.
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The reaction was incubated at room temperature under nitrogen for 3 h with gentle
vortexing every 20 min. The final pH was 12~13. Next, the β-elimination reaction was
terminated by addition of 5 μL of 10% TFA and the resulting solution was desalted with a
POROS 20 R2 micro column. The purified peptide solution was dried and reconstituted
in 50 μL of 0.5 M thiocholine solution freshly prepared in 0.1 M NaOH. The mixture was
incubated at 50 C° under nitrogen for 5 h at pH 8~9. The reaction was terminated by the
addition of 5 μL 10% TFA.

Phosphorylation of Calcium-independent Phospholipase A2β by Protein Kinase A
Purified iPLA2β(His)6 was obtained as previously described by Jenkins et al. [33]. The
catalytic subunit of protein kinase A (400U) was incubated with 100 μg of purified
iPLA2β(His)6 in 40 mM Tris-HCl buffer, pH 7.4 containing 20 mM magnesium acetate
and 0.3 mM ATP for 1 h at 30°C. The resultant phosphorylated enzyme was dialyzed
against 1L deionized water for 8 h using a Slide-A-Lyzer® MINI Dialysis Unit. The
dialyzed iPLA2β sample was dried in a SpeedVac apparatus (Savant, Holbrook, NY) and
reconstituted in 50 μL of 0.2% Rapigest in 50 mM NH4HCO3. Next, 2.5 μL of 100 mM
DTT was added to a final concentration of 5 mM. The sample was then incubated at 60°C
for 30 min before 6 μL 150 mM iodoacetamide was added to quench the reduction and
initiate alkylation. The sample was incubated for an additional 30 min in the dark.
Trypsin was added to the solution at an enzyme to protein ratio of 1:30 (w:w). The total
volume of the sample solution was adjusted to 100 μL with 50 mM NH4HCO3.
500fmol/μL protein sample was incubated at 37 °C for 2 h then acidified with 10 μL 10%
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TFA to lower the pH to < 2. The sample was again incubated at 37 °C for 30 min and
centrifuged at 13,000 rpm to pellet the hydrolyzed Rapigest. The resultant supernatant
was used for thiocholine modification.

BEMA of Trypsinized Calcium-independent Phospholipase A2β with Thiocholine
Trypsinized iPLA2β samples were dried in a SpeedVac apparatus and reconstituted in 50
μL deionized water follow by the addition of 38 μL DMSO and 12 μL of absolute ethanol.
The trypsinized protein solution was then divided into 2 equal aliquots of 50 μL that were
separately modified with one of two protocols.
Protocol I: 25 μL of saturated Ba(OH)2 was added to the sample and the reaction was
incubated at room temperature under a nitrogen atmosphere for 1 h and gently vortexed
every 20 min. The final pH of the reaction mixture was pH 12~13. 1M thiocholine was
freshly prepared in water and 50 μL was directly added to each reaction. This reaction
was incubated at room temperature for 3 h at pH 8-9 and then terminated by the addition
of 10 μL 10% TFA.
Protocol II: 25 μL of saturated Ba(OH)2 was added to the sample and the reaction was
incubated at room temperature under a nitrogen atmosphere for 3 h and gently vortexed
every 20 min. The final pH was 12-13. Next, the β-elimination was terminated by
addition of 10 μL of 10% TFA and the resulting solution was desalted with a POROS 20
R2 micro column. The purified peptide solution was dried and reconstituted in 50 μL of
0.5 M thiocholine solution freshly prepared in 0.1 M NaOH. This reaction was incubated
at 50C° under nitrogen for 5 h at pH 8-9. The reaction was terminated by the addition of
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5 μL 10% TFA.

Comparative Quantitation of Phosphoproteins using Natural Abundance Thiocholine
and Thiocholine-13C,d3 with the Model Protein β-Casein
50 μL 1 mg/mL β-Casein solution prepared in water was mixed with 50 μL 0.2%
Rapigest in 100 mM NH4CO3. The protein sample was subjected to in-solution tryptic
digestion as described above. The resulting trypsinized β-Casein was concentrated with a
SpeedVac to ~50 μL and divided to 2 equal aliquots. Aliquot 1 was subject to BEMA with
natural abundance thiocholine as the Michael donor while aliquot 2 was modified with
stable isotope labeled thiocholine-13C,d3 both using Protocol I for iPLA2β covalent
modification as described above. Modified trypsinized β-Casein in aliquots 1 and 2 were
then mixed in selected ratios (v:v; aliquot 1: aliquot 2, or light: heavy): five independent
replicates at 1:1 and three independent replicates at 1:2, 1:3, 1:4, 4:1, 3:1 and 2:1 ratios
respectively were performed. Experimental ratios from mass spectrometric analyses were
compared to expected ratios to evaluate the reproducibility and linearity of the method.

Sample Purification
All samples subject to mass spectrometric analysis were desalted with POROS 20 R2
micro columns according to the procedure by Thingholm et al. [34]. Briefly, a POROS 20
R2 micro column was assembled by stamping out a small plug of C8 material from a 3 M
Empore C8 extraction disk using a HPLC syringe needle and placing this plug in the
constricted end of a GELoader tip. Next, POROS R2 beads that were suspended 50%
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acetonitrile at 5mg/200 µL were packed in the GELoader tip by pressing air through the
micro column using an Eppendorf syringe. The length of the packed POROS R2 resin
was about 3-6 mm. Then the column was washed with 30 µL 50% acetonitrile and
equilibrated with 30 µL 0.1% trifluoroacetic acid. Sample solution was then loaded onto
the POROS R2 micro column. The sample was slowly passed through the micro column
by pressing air through the using a Eppendorf syringe. The column was washed twice
with 30 µL 0.1% trifluoroacetic acid and the bounded peptides were eluted first using 30
µL 70% acetonitrile with 0.05 % trifluoroacetic acid, then 5 µL 30% acetonitrile with
0.05% trifluoroacetic acid.

MALDI-TOF/TOF Mass Spectrometric Analyses
MALDI-TOF/TOF mass spectrometric analyses were performed using a 4800
MALDI-TOF/TOF Analyzer (Applied Biosystems, Foster City, CA). 1 μL of each peptide
sample eluted from a POROS R2 micro column was mixed with 1μL α-CHCA solution
and 0.5 μL of the mixture was spotted on an Opti-TOF 384 well plate. Mass spectra of all
peptide samples were acquired in the positive ion mode by averaging 500 consecutive
laser shots (50 shots per subspectrum with ten total subspectra) with default calibration.
MS2 analyses of the peptide samples were accomplished by collision-induced
dissociation (CID) using air at medium pressure.

HPLC-ESI-MS2/MS3 Mass Spectrometric Analyses
Trypsinized protein and peptide samples desalted with POROS 20 R2 micro columns
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were dried and reconstituted in 0.1% formic acid before injection and separation using a
Surveyor HPLC system (Autosampler and Pump, ThermoFisher, San Jose, CA) equipped
with a reverse-phase C18 PepMap100 Nano-LC column (75 μm I.D. x 15 cm, 3 μm, 100
angstrom; Dionex, Sunnyvale, CA). Flow rate was maintained at 220-280 nL/min.
Samples eluting from the column were directed to the nanospray apparatus (i.e.
NanoMate HD with LC coupler, Advion Bioscience Ltd., Ithaca, NY) and sprayed
directly into an LTQ-Orbitrap mass spectrometer (ThermoFisher, San Jose, CA) at a
spray voltage of 1.7 kV in the positive ion mode. Model peptides and trypsinized β-casein
samples were eluted with a gradient from 100% A to 50% A, 50% B in 20 min (Buffer A:
90% water, 10% acetonitrile, 0.1% formic acid; Buffer B: 10% water, 90% acetonitrile,
0.1% formic acid, v:v) and were subject to data-dependent MS2 analyses: full mass scans
were acquired using an Orbitrap (300-1600 m/z, mass resolution = 30,000) followed by
product-ion scans in the LTQ of the five most abundant ions. iPLA2β samples, modified
by the two optimized protocols, were analyzed first in survey runs, which consisted of a
90-min gradient from 100% A to 50% A, 50% B and data-dependent MS2 analyses: full
mass scans in the Orbitrap (300-1600 m/z, mass resolution = 30,000) were followed by
product-ion scans in the LTQ of the five most abundant ions. The ions of interest from the
survey runs were then included in the parent mass list of the target runs. The target runs
consisted of a 180-min gradient from 100% A to 75% A, 25% B (120 min), then to 50%
A, 50% B (60 min) and data-dependent MS2/MS3 analyses: full mass scan in the Orbitrap
(300-1600 m/z, mass resolution = 30,000) were followed by product-ion scans in the LTQ
of the three most abundant ions from the parent mass list and the MS3 scans in the LTQ
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of the ten most abundant fragment ions following each of the three product-ion scans.
The normalized collision energy for CID was set at 25 for all data-dependent scans.

Data Processing
The local MASCOT server was used to conduct all database searches. A single-protein
(iPLA2β) database was created by in silico trypsinolysis. Thiocholine and
thiocholine-13C,d3 with neutral loss trimethylamine and thiolate were integrated into
MASCOT for customized processing of the designed covalent modifications for serine
and threonine residues at the MS2 level. Carbamidomethylation (C) was set as the fixed
modification for trypsinized iPLA2β samples.
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2.4 Results and Discussion

The chemical replacement of the phosphate on serine and threonine residues via
β-elimination and Michael addition has been widely used for analyses of
phosphopeptides. However, an efficient method that concomitantly yields high sensitivity,
minimal side reactions and informative diagnostic ions suitable for quantitative analyses
of both pS and pT-containing peptides in the phosphoproteome has remained elusive.
Thiocholine was chosen as the Michael donor in this study because of the extraordinary
sensitivity of the quaternary amine for ionization during ESI and its utility in creating
diagnostic fragment ions resulting from the neutral loss of trimethylamine and the
thiocholine thiolate. The syntheses of both thiocholine and stable isotope labeled
thiocholine-13C,d3 are straightforward (Scheme 1.3). Model peptides containing either
phosphoserine (FQpSEEQQQTEDELQDK) or phosphothreonine (DHTGFLpTEYVATR)
were chosen to assure that reaction conditions were developed that facilitate assessment
of either serine or threonine phosphorylation sites. For proteins, either the traditionally
employed model protein β-Casein was used or phosphorylation of the signaling protein
iPLA2β by protein kinase A (PKA) was studied.

Optimization of BEMA Conditions and Ionization Efficiency
The overall reaction yield is an important factor for the success of the BEMA
strategy. Given that the reaction rates of phosphorylated serine and threonine residues are
quite different for either β-elimination or Michael addition owing to the electron-donating
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effect of the β-methyl group of threonine residue (Appendix C), the reaction conditions
were optimized for phosphorylated serines and threonines individually by using the
model phosphopeptides FQpSEEQQQTEDELQDK and DHTGFLpTEYVATR. Through
the use of Ba(OH)2, a controlled high-yield conversion of FQpSEEQQQTEDELQDK to
its corresponding dehydro-alanine derivative was accomplished within 40 min (Figure
2.1). The addition of thiocholine then resulted in the rapid (< 60 min) synthesis of the
desired thiocholine adduct. Based upon integrated UV absorbance, these sequential
transformations were accomplished in near quantitative yield (Figure 2.1). To ensure the
completeness of the reaction for more complicated samples, the reaction times were set at
1 h and 3 h for β-elimination and Michael addition, respectively.
The mass spectrometric utility of this covalent conversion was demonstrated by a
marked increase in ionization efficiency with ESI illustrated by the total ion current
tracing obtained during reversed-phase chromatography after injection of identical
amounts of the thiocholine-modified peptide and its non-modified phosphopeptide
precursor. This remarkable increase in ionization efficiency is engendered by the
replacement of acidic phosphate with quaternary amine bearing thiocholine that possesses
an endogenous positive charge and is extraordinarily sensitive to ionization during the
electrospray process (Figure 2.2-A). The detection limit of this method using ESI is at the
attomole level (Figure 2.3). Using MALDI, a 3-fold increase in MS signal was present
after derivatization as demonstrated by analysis of a sample containing equal amounts of
phosphopeptide and thiocholine-modified phosphopeptide onto a MALDI plate using
α-CHCA as matrix (Figure 2.2-B).
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Phosphorylated threonines, possessing secondary hydroxyls, generally have
slower reaction rates during both β-elimination and Michael addition in comparison to
their primary hydroxyl counterparts [35]. Simply increasing the incubation temperature
and/or incubation time results in increased formation of side products and is not
productive [11, 36-37]. However, by purification of the dehydro-alanine intermediate
from β-elimination and through the use of nitrogen protection, the overall reaction yield
for Michael addition using the model peptide, DHTGFLpTEYVATR, has been greatly
improved (Figure 2.4-2.6). These modification strategies individualized for pS or pT
residues greatly maximize the effectiveness of BEMA for phosphoproteomics.
Phosphorylated tyrosines are stable and are not altered under the alkaline conditions
employed in this study [35].

Fragmentation of Thiocholine-modified Peptides
In addition to dramatically increasing ionization efficiency in ESI-MS,
thiocholine derivatization exhibits the unique ability to generate diagnostic triads of
informative fragment ions resulting from both the routine peptide bond cleavage and the
facile neutral loss of either trimethylamine (59 Da) or thiocholine thiolate (119 Da)
during CID in MS2 and MS3 scanning. This results in a greatly improved identification
algorithm for target peptides. A representative ESI-product-ion spectrum of the triply
charged molecular ion of the thiocholine-modified peptide FQS*EEQQQTEDELQDK is
shown in Figure 2.7-A. Analysis of the fragmentation pattern demonstrated multiple
informative b and y ions necessary for sequence identification. As shown in the expanded
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spectrum, a representative peptidic fragment ion b5+ (m/z = 722.3) is accompanied by its
neutral loss counterparts b5 - 59+ (m/z = 663.2) and b5 - 119+ (m/z = 603.2) after loss of
trimethylamine or thiocholine thiolate, respectively (nomenclature of peptide fragment
ions is presented in Appendix D). The concurrence of these diagnostic triads of fragment
ions obtained through conventional CID represent key informative features that can
further facilitate the identification of peptides and increase the confidence of assignment
of

the

phosphorylated

residue(s)

on

peptides

containing

multiple

potential

phosphorylation sites.. Furthermore, use of MS3 for the thiocholine-containing ion y14+2
(m/z = 904.4) demonstrated that neutral loss of trimethylamine is the dominant
fragmentation pathway leading to a signature neutral loss product at m/z 875.1 (M - 59)
(Figure 2.7-B). Thus, introduction of the thiocholine side chain and subsequent
fragmentation resulted in the generation of suites of diagnostic triads of fragment ions in
both MS2 and MS3 experiments that helped not only to enhance sequence coverage, but
also to increase the confidence of the phosphopeptide identification and the specific
location

of

the

modified

residue.

Tandem

mass

spectrometric

analyses

of

FQS*EEQQQTEDELQDK were also conducted on the singly charged molecular ion
with MALDI and the doubly charged molecular ion with ESI. In MALDI experiments,
the product-ion spectrum of the molecular ion at m/z 2082.62 (+) contains a dominant
signature ion at m/z 2023.7 (+) (Figure 2.7-C). This ion resulted from the neutral loss of
trimethylamine (59 Da) from the thiocholine side chain of the molecular ion with
minimal sequence-informative b and y ions. The product-ion spectrum obtained with ESI
of the doubly charged molecular ion showed a strong neutral loss peak from the
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molecular ion at m/z 1012.5 (+2) (Figure 2.8). In MALDI, peptides are almost always
singly charged [38]. With the low kinetic energy, singly charged thiocholine-containing
peptides require higher collision energy to induce peptidic chain fragmentation relative to
the neutral loss of trimethylamine. Therefore, the neutral loss is more prone to occur than
the formation of b and y ions in low-energy CID, leading to a dominant neutral loss
pattern. Similarly, in ESI, neutral loss represents a pathway that requires lower energy to
induce fragmentation of the doubly charged parent ion. However, when the peptide is
triply charged, with the higher vibrational energy derived from collisions at the increased
kinetic energy gained during acceleration, peptide chain fragmentation becomes more
favorable than the neutral loss of trimethylamine leading to the production of a sequence
of informative b and y ions [39]. Although neutral loss of trimethylamine is no longer
dominant in this case, it can still occur on thiocholine containing fragment ions, which
together with the ions from neutral loss of thiocholine thiolate provides additional
confirmatory sequence information and facilitates the assignment of phosphorylation
sites. Moreover, as described above (Figure 2.7-B), neutral loss of trimethylamine
becomes favorable again in MS3, producing a signature neutral loss (SNL) peak during
CID, which adds an additional dimension to the identification of peptide phosphosites.
Although the majority of the tryptic peptides are doubly charged using ESI owing to
basic amino acid residues on both N- and C- termini using conventional trypsinolysis, the
modified phosphopeptides typically possess a charge state of 3 or higher due to the
additional positive charge introduced by thiocholine. Through combining tryptic
proteolysis with thiocholine modification, the majority of the thiocholine-modified
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peptides will be triply charged or higher, thereby leading to a rich repertoire of diagnostic
triads of peptidic fragment ions and ions from neutral loss of trimethylamine and the
thiocholine thiolate for significant improvement in the identification of phosphorylation
sites during ESI-MS2 analyses. In addition, ions containing intact thiocholine side chains
losing trimethylamine produce a signature neutral loss pattern in MS3, greatly improving
the confidence of the identification of phosphopeptides and the localization of the
phosphorylated residue(s) in peptides containing more than one potential phosphosite or
in the elucidation of phosphorylation patterns in cases where multiple sites are
phosphorylated.

Identification of Protein Kinase A Phosphorylation Sites in Calcium-independent
Phospholipase A2β (iPLA2β)
iPLA2β is an important phospholipase in cellular signaling that contributes to
diverse cellular processes including arachidonic acid release, insulin secretion, calcium
signaling, and apoptosis [33, 40-42]. We used the developed method to identify in vitro
PKA phosphorylation sites of iPLA2β to demonstrate the application of this method in a
biologically relevant system. Prior to BEMA modification, the potential interference from
free thiols must be eliminated [43]. Previously, perfomic acid oxidation was widely used
to oxidize cysteine residues directly or convert cysteine disulfide bonds to cysteic acid
residues [44-45]. However, although harsh oxidation may convert all cysteines to cysteic
acid, it also leads to additional oxidation and an undesirable increase the chemical
diversity and complexity of the sample [46-47]. Other potentially susceptible moieties
53

include alkylated cysteines, either endogenous or introduced by reductive alkylation, as
well as O-glycosylated serines and threonines. These residues could cause ambiguities
similar to an intact cysteine because they could also be converted to the same modified
residues as pS/pT under alkaline conditions in the presence of strong nucleophiles
[48-49]. However, using Ba2+ as the catalyst coupled with well-controlled reaction
conditions, β-elimination of alkylated cysteines or O-glycosylated serines and threonines
occurs at rates two orders of magnitude more slowly than β-elimination from pS/pT
whereas unphosphorylated serine and threonine residues are unaffected [35]. Under the
conditions employed in this study, reductive alkylation does not interfere with BEMA
targeting of phosphopeptides, and, thus, many side products and potential ambiguities are
avoided. The identification of peptide CaNdVMGPS*GFPIHTAMK in iPLA2β contains
both alkylated cysteine and thiocholine-modified serine residues showing the
compatibility of the routine reductive alkylation with Ba2+ catalyzed BEMA (Figure 2.9).
The fragmentation patterns and sequence coverage of the trypsin-generated
phosphopeptides that were identified in the PKA phosphorylated iPLA2β with and
without thiocholine modification are demonstrated for the peptide SSGAAPTYFRPNGR
(582-595). The product-ion spectrum of the phosphopeptide p(SS)GAAPTYFRPNdGR
(Figure 2.10-B) exhibits a strong peak corresponding to the neutral loss of H3PO4 from
the doubly charged molecular ion with key peptidic chain cleavage products y13 and b1 at
the Ser-Ser peptide bond missing from the spectrum precluding discrimination of
phosphorylation at residues Ser582 or Ser583.

In sharp contrast, the product-ion

spectrum of SS*GAAPTYFRPNdGR (Figure 2.10-A) shows an abundant diagnostic y13+3
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ion at m/z 499.4 as well as its satellite neutral loss ions (shown in the expanded spectrum),
which led to the unambiguous assignment of phosphorylation at residue Ser583. In
low-energy CID, phosphopeptides are prone to lose a neutral phosphoric acid to form a
five-member oxazole ring, which is a preferred fragmentation pathway for
phosphopeptides [12]. The five-member ring prevents peptide bond cleavage at the site of
phosphorylation and informative b and y ions resulting from that particular bond cleavage
are missing, thus preventing conclusive identification of the phosphorylation site(s) in
many cases. Therefore, although a phosphopeptide is easily identified through its neutral
loss of 98 Da, the site of phosphorylation is often difficult to determine precisely by
conventional means. In summary, replacing the phosphate with thiocholine prevents the
cyclo-elimination of phosphoric acid in CID owing to the increased charge state of
modified peptides thus improving sequence coverage and facilitating the unambiguous
identification of the specific phosphorylated residue.
As shown in Table 1, 32 different phosphorylation sites were identified in iPLA2β
phosphorylated samples examined using the customized protocols optimized for either pS
or pT. These phosphorylation sites originated from a total of 16 unique sequences. Figure
2.11-A shows the product-ion spectrum of triply charged peptide EIS*VADYTSHER
(26-37). The spectrum consists of b and y ions with diagnostic triads of all thiocholine
containing peptidic fragment ions. Shown in the expanded spectrum are representative
diagnostic triads from y10+2 and b6+ fragmentation ions resulting from peptide bond
cleavage (m/z = 633.6 and 716.3) and further neutral loss of trimethylamine (-59 Da, m/z
= 603.3 and 657.2) and the thiocholine thiolate (-119 Da, m/z = 574.1 and 597.2). The
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characteristic neutral losses in MS2 level are incorporated into MASCOT to contribute to
the identification of the peptide and location of the phosphorylation site(s).
A promising future prospect of this approach is the use of this chemical property
in a weighted scoring system for ion identification that uses these unique and predictable
diagnostic triads of fragmentation ions from thiocholine-modified peptides to facilitate
identification of phosphorylated peptides and phosphosites in singly and multiply
phosphorylated peptides. Among the ions generated in MS2 fragmentation, the ten most
abundant ions were chosen to be further fragmented at the MS3 level. Examination of the
y10+2 ion at m/z 633.6 (amongst the top ten ions selected) demonstrated that it also
possesses the intact thiocholine side chain, which led to its signature neutral loss pattern
in its MS3 spectrum (Figure 2.11-B). The ion peak at m/z 604.0 corresponds to the neutral
loss of trimethylamine from the precursor y10+2 at m/z 633.6. From the example of the
peptide EIS*VADYTSHER, it is clear that the thiocholine side chain enabled a unique
tandem fragmentation pattern ideal for proteomic analyses, since sequencing of the
peptide at the MS2 level is not disrupted by the neutral losses of either trimethylamine or
thiocholine thiolate but rather strengthened by the presence of diagnostic triads of
fragment ions in conjunction with the signature neutral loss at MS3 level. Collectively,
these features serve to provide important structural information facilitating both the
identification of the peptide as well as the location of the precursor ion to facilitate
unambiguous identification of the phosphorylated residues. In the current study, nine out
of 16 unique sequences demonstrated at least one ion with a signature neutral loss during
MS3 scanning underscoring the utility of the developed method. Although neutral-loss
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information has been incorporated in MASCOT as part of the variable modification of
thiocholine, MS3 spectra with signature neutral loss patterns must be manually selected at
the present time.

Comparative Quantitation of Phosphoproteins using Natural Abundance Thiocholine
and Thiocholine-13C,d3 with Model Protein β-Casein
Comparative quantitation via BEMA with thiocholine and thiocholine-13C,d3 was
evaluated with the model phosphoprotein β-casein to determine the reproducibility and
linearity of the developed method. As described in experimental procedures, two equal
aliquots

of

trypsinized

β-casein

were

modified

with

either

thiocholine

or

thiocholine-13C,d3. The light and heavy thiocholine containing peptides of β-casein
were then mixed at different ratios (v:v) as follows;: five independent replicates at 1:1,
three independent replicates at 1:2, 1:3, 1:4, 4:1, 3:1 and 2:1 respectively. The tryptic
phosphopeptide FQpSEEQQQTEDELQDK was chosen to characterize the quantitation
of the phosphorylation of β-casein. Thiocholine and thiocholine-13C,d3-modified peptides
FQS*EEQQQTEDELQDK and FQS**EEQQQTEDELQDK were compared by their ion
intensities at their prevailing charge state (+3) at the time of elution. The average adjusted
experimental ratio of ion intensities for five replicates at 1:1 is 0.96 with a standard
deviation of 0.02. Thus, this method shows comparable reliability to similar experiments
employing isotope-coded affinity tags [50]. The full-mass spectrum from the XIC of two
modified peptides at the time of the elution is shown in Figure 2.12 with the well
recognized (M + 4) isotopologue pattern. The experimental ratios of peak intensities were
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obtained for samples mixed in selected ratios and plotted against theoretical values to
yield a correlation coefficient of R2 = 0.99. Furthermore, there was no chromatographic
shift between the light and heavy thiocholine-modified peptides (Figure 2.13). Overall,
stable isotope ratiometric comparisons demonstrated the anticipated quantitative accuracy
in both reproducibility and linearity using heavy and light thiocholine modification.
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2.5 Conclusion and Perspective

We have demonstrated a strategy for the facile, sensitive and precise detection,
identification and quantitation of serine/threonine phosphorylation in proteins. By
introducing thiocholine into the target peptides, a powerful mass spectrometric
methodology is added that greatly increases the sensitivity of phosphosite identification,
enriches the repertoire of observable fragmentation ions from the production of a higher
charge state, and provides diagnostic triads of fragment ions through signature neutral
loss patterns. The development of an affinity purification method for quaternary amines
such as those previously demonstrated using calixirenes [52] may greatly facilitate the
large scale integrated use of this strategy in cellular systems.
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2.7 Table Legends

Table 2.1
Identification of phosphorylation sites in iPLA2β phosphorylated by protein kinase
A (PKA). Tryptic iPLA2β peptides were modified by two different protocols
optimized for either phosphoserine or phosphothreonine as described in the
Materials and Methods section. The thiocholine-modified peptides were desalted,
separated using reverse-phase nanobore HPLC and analyzed with an LTQ-Orbitrap
system. Candidate peptides were identified using MASCOT with the designated
thiocholine modification as well as common amino acid modifications as described
in the Materials and Methods section.
16 unique sequences and 32 different phosphorylation sites were identified. “*” denotes
phosphorylation sites; “(*)” denotes that more than one phosphorylation site was
identified in the same peptide. Those that were not concurrent are indicated by “/”
whereas “+” indicates peptides that possessed multiple concurrent phosphorylation sites.
Superscripts “ace”, “ac”, “d” and “o” denote the following modifications: acetylation
(N-terminus), acetylation (K), deamidation (NQ) and oxidation (M), respectively. All
cysteine residues were carbamidomethylated. Identified peptides with missed cleavages
are listed together with the completely trypsinized peptides as indicated by bold bordered
boxes. Peptides which yielded a signature neutral loss pattern in MS3 are highlighted in
bold.
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Table 2.1
Sequence#

Sequence

Phosphorylation
Site(s)

Δm
(ppm)

Ion Score

1-23

MQFFGRLVNdTLSSVTNdLFS*NdPFR

S13/S19

2.99

10.8

24-37

( )

VKEIS*VADYTS * HER

S28/S34

-1.79

38.7

24-37

VKEIS*VADYTS*HER

S28+S34

-1.69

23.7

( )

26-37

EIS*VADYTS * HER

S28/S34

-1.86

32.5

26-37

EIS*VADYTS*HER

S28+S34

-0.99

23.0

38-53

VREEGQLILFQNAS*NR

S51

-1.01

33.8

NAS*AGLNQVNdKQGLTPLHLACQMGK

S210

2.87

5.7

S252/T258

-1.24

31.7

S276+S277+S281

-1.35

12.2

T313+S314+T319

0.45

4.6

208-232

d

( )

246-261

CN VMGPS*GFPIHT * AMK

266-282

ace

306-327

ace

307-327

GCDVDSTSAAGNT*ALHVAVMoR

T319

1.29

12.2

393-405

ace

S404

3.91

7.4

396-405

QLQdDLMPIS*R

S404

-3.46

12.5

GCAEMoIISMDS*S*QIHS*Kac
d

o

RGCDVDST*S*AAGN T*ALHVAVM R

ac

d

d

ISK Q LQ DLMPIS*R
( )

406-417

ARKPAFILS*S * MR

S414/S415

-1.02

37.0

406-420

ARKPAFILS*S(*)MRDEK

S414/S415

-2.00

9.3

408-417

( )

KPAFILS*S * MR

S414/S415

-1.76

32.0

408-420

KPAFILS*S(*)MRDEK

S414/S415

-1.29

20.0

479-489

S*MAYMRGVYFR

S479

-5.00

13.6

492-511

DEVFRGS*RPYESGPLEEFLKac

S498

1.60

6.2

497-511

GS*RPYES*GPLEEFLK

S498+S503

-1.78

13.2

497-511

GS*RPYES(*)GPLEEFLK

S498/S503

-0.28

54.5

T518/T521

-3.32

6.3

T521

3.18

16.3

T531/S535

-1.84

28.0

T531+T533

0.61

15.5

S583/T588

-0.89

39.9

S634/S638/T641

3.54

13.1

o ( )

513-524

EFGEHT*KM T * DVK

520-527

ace

MT(*)DVKacKPK
( )

528-537

VMLT*GTLS * DR

528-537

VMoLT*GTLS*DR
( )

d

582-595

SS*GAAPT * YFRPN GR

632-643

ace

644-665

SPQVPVTCVDVFRPS*NPWELAK

S658

1.07

3.6

692-705

ace

S696

2.56

4.5

694-705

AWS*EMVGIQYFR

S696

-1.95

22.1

KacLS*IVVS(*)LGT(*)GR

ARAWS*EMoVGIQdYFR
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2.8 Figure Legends

Figure 2.1 Optimization of β-elimination and Michael addition (BEMA) reaction
conditions for phosphorylated serine containing peptides using the model peptide
FQpSEEQQQTEDELQDK.
The model peptide FQpSEEQQQTEDELQDK was modified using BEMA with
thiocholine as described in the Materials and Methods section. The β-elimination and
Michael addition reactions were terminated at the indicated time intervals. The resultant
reaction mixtures were separated on an HPLC reverse-phase column (C18, 150 x 4.6mm)
and the peptides were detected with a UV monitor at λ = 206 nm. The β-elimination
reaction was complete within 40 mins and Michael addition was complete in
approximately 60 min.

Figure 2.2 Comparison of the ionization efficiency of the phosphopeptide
FQpSEEQQQTEDELQDK ▲)
(

and

its

thiocholine-modified

derivative

FQS*EEQQQTEDELQDK (■).
The model peptide FQpSEEQQQTEDELQDK was modified via BEMA with thiocholine
as described in the Materials and Methods section and an equivalent amount of the
original unmodified phosphopeptide FQpSEEQQQTEDELQDK was added. The
quantitative yields of the BEMA reactions were

similar to those shown in Figure 1.

“pS” indicates the phosphorylation site and “S*” indicates the thiocholine-modified site.
A. Separation of the peptide mixture using a reverse-phase C18 column and analysis
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employing an ESI-LTQ-Orbitrap as described in the Materials and Methods section. The
full-mass scan extracted ion chromatography (XIC) of ions at m/z 694.983 (+3) and
1031.417 (+2) with normalized ion intensities is presented. The ion at m/z 694.983
corresponds to the triply charged molecular ion (dominant charge state) of
FQS*EEQQQTEDELQDK (■) and the ion at m/z 1031.417 corresponds to the doubly
charged molecular ion (dominant charge state) of FQpSEEQQQTEDELQDK (▲). The
XIC shows a marked increase in ionization efficiency of the peptide after thiocholine
modification.
B. The full mass spectrum of the 1:1 peptide mixture obtained with a 4800
MALDI-TOF/TOF Analyzer with normalized ion intensity. The ion peak at m/z 2061.52
corresponds to the singly charged molecular ion of FQpSEEQQQTEDELQDK (▲) and
the ion peak at m/z 2082.62 corresponds to the singly charged molecular ion of
FQS*EEQQQTEDELQDK (■). A 3-fold increase in ionization efficiency of the peptide
after thiocholine modification was observed with MALDI-MS.

Figure

2.3

Detection

limit

for

the

thiocholine-modified

peptide

FQS*EEQQQTEDELQDK.
Extracted ion chromatogram (XIC) and product-ion spectra were acquired with an
LTQ-Orbitrap as described in the Materials and Methods section.
A.

Extracted

ion

chromatogram

of

the

thiocholine-modified

model

peptide

FQS*EEQQQTEDELQDK at m/z 694.983 (+3) at the concentration of 500 amol/ul (Ion
counts = 2.01E3).
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B.

The

full

mass

spectrum

of

the

thiocholine-modified

model

peptide

FQS*EEQQQTEDELQDK at m/z 694.983 (+3) at the concentration of 500 amol/ul (Ion
counts = 2.01E3, Signal-to-Noise = 4).

Figure 2.4 Optimization of β-elimination and Michael addition reaction conditions
for the phosphorylated threonine containing peptide: DHTGFLpTEYVATR (i).
The β-elimination of DHTGFLpTEYVATR was terminated at the indicated time intervals.
The resultant reaction mixtures were separated on an HPLC reverse-phase column (C18,
150x4.6mm) and the peptides were detected with a UV monitor at λ = 206 nm.

Figure 2.5 Optimization of β-elimination and Michael addition reaction conditions
for the phosphorylated threonine containing peptide: DHTGFLpTEYVATR (ii).
The phosphothreonine containing peptide, DHTGFLpTEYVATR, was subject to 3h
Ba(OH)2 catalyzed β-elimination followed by overnight room-temperature incubation
with thiocholine to effect Michael addition. The full mass spectrum of the resulting
thiocholine addition product was acquired on a 4800 MALDI-TOF/TOF analyzer. The
spectrum was remarkable for the predominance of the undesired oxidation of the histidine
residue (denoted Ho) and N-terminal acetylation (denoted

ace

D) (m/z 1549.47). Only

minimal amounts of the desired Michael adduct (m/z 1610.47) was observed under these
conditions.
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Figure 2.6 Optimization of β-elimination and Michael addition reaction conditions
for the phosphorylated threonine containing peptide: DHTGFLpTEYVATR (iii).
The β-elimination and Michael addition of thiocholine to DHTGFLpTEYVATR were
carried out under nitrogen and the intermediate products of β-elimination were purified
with a POROS R2 micro-column as described in the Materials and Methods section
before undergoing Michael addition at pH = 8-9. Extracted ion chromatogram (XIC) and
product-ion spectra were acquired with an LTQ-Orbitrap as described in the Materials
and Methods section.
A.

Extracted

ion

chromatogram

of

the

thiocholine-modified

peptide

DHTGFLT*EYVATR and its β-elimination product DHTGFLTdeEYVATR after 5h of
incubation with thiocholine at room temperature demonstrated minimal thiocholine
addition.
B.

Extracted

ion

chromatogram

of

the

thiocholine-modified

peptide

DHTGFLT*EYVATR and its β-elimination product DHTGFLTdeEYVATR after 5h of
incubation with thiocholine at 50°C showing a significantly improved yield.
C./ D. The product-ion spectra of DHTGFLT*EYVATR of the two XIC peaks from
Figure S3-B at RT = 21.96 min and 25.32 min. No substantial differences between the
spectra were observed. The difference in retention times implies the formation of
diastereomers during the Michael addition reaction.
E. The product-ion spectrum of the β-elimination product DHTGFLTdeEYVATR.
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Figure

2.7

Fragmentation

of

the

thiocholine-modified

peptide

FQS*EEQQQTEDELQDK.
A.

The

product-ion

spectrum

of

the

triply

charged

molecular

ion

of

FQS*EEQQQTEDELQDK at m/z 694.983 was obtained with an ESI-LTQ-Orbitrap as
described in the Materials and Methods section. The fragment ion resulting from the
neutral loss of trimethylamine from the parent ion was not detected. Shown in the
expanded spectrum is an example of the diagnostic triad consisting of the b5+ ion
resulting from peptide bond cleavage (m/z = 722.3) and further neutral losses of
trimethylamine (-59 Da, m/z = 663.2) or the thiocholine thiolate (-119 Da, m/z = 603.2).
“S*” indicates the thiocholine-modified site.
B. The MS3 spectrum of the y14+2 ion at m/z 904.4 resulting from the fragmentation of the
triply charged molecular ion of FQS*EEQQQTEDELQDK at m/z 694.983. The ion peak
at m/z 875.1 corresponds to the doubly charged fragment ion generated from the neutral
loss of trimethylamine from the parent ion y14+2.
C.

The

product-ion

spectrum

of

the

singly

charged

molecular

ion

of

FQS*EEQQQTEDELQDK at m/z 2082.62, obtained with a 4800 MALDI-TOF/TOF
Analyzer as described in the Materials and Methods section. The ion peak at m/z 2023.72
corresponds to the fragment ion resulting from the neutral loss of trimethylamine from
the parent ion. Shown in the expanded spectrum are the low-abundance y ions.
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Figure 2.8 The product-ion spectrum of the doubly charged molecular ion for the
thiocholine-modified model peptide FQS*EEQQQTEDELQDK at m/z 1041.964,
acquired with an LTQ-Orbitrap as described in the Materials and Methods section.
The ion peak at m/z 1012.5 corresponds to the fragment ion generated from the neutral
loss of trimethylamine from the parent ion.

Figure 2.9 The product-ion spectrum of the thiocholine-modified peptide
CaNdVMGPS*GFPIHTAMK at m/z 616.958, acquired with an LTQ-Orbitrap as
described in the Materials and Methods section.
The identification of the PKA mediated phosphorylation of iPLA2β at Ser252 following
reductive alkylation and thiocholine modification demonstrates that the peptide contains
both an alkylated cysteine and a thiocholine-modified serine, showing the compatibility
of routine reductive alkylation with Ba2+ catalyzed BEMA.

Figure 2.10 Sequence coverage comparison between the thiocholine-modified
peptide SS*GAAPTYFRPNdGR and the phosphopeptide p(SS)GAAPTYFRPNdGR
identified in protein kinase A (PKA) phosphorylated calcium-independent
phospholipase A2β (iPLA2β).
A. Identification of PKA mediated phosphorylation of iPLA2β at Ser583 via thiocholine
modification. SS*GAAPTYFRPNdGR was identified after in vitro PKA catalyzed
phosphorylation of iPLA2β with subsequent thiocholine modification as described in the
Materials and Methods section. Spectra were acquired using an LTQ-Orbitrap equipped
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with an electrospray ion source. The product-ion spectrum of the triply charged molecular
ion (dominant charge state) at m/z 528.264 shows a dominant y13+3 peak leading to
unambiguous assignment of the phosphosites. Also shown in the expanded spectrum
(relative intensity zoom = 25%) are the diagnostic triad consisting of y13+3 (m/z = 499.4),
the ion from the neutral loss of trimethylamine, y13 - 59+3 (m/z = 479.1), and the ion from
neutral loss of the thiocholine thiolate, y13 - 119+3 (m/z = 459.3), as well as the peak
corresponding to the loss of the thiocholine thiolate from the molecular ion M - 119+3
(m/z = 488.9).
B. Identification of PKA mediated phosphorylation of iPLA2β at Ser582/Ser583 without
thiocholine

modification.

p(SS)GAAPTYFRPNdGR

was

identified

in

PKA

phosphorylated iPLA2β without thiocholine modification by ESI-LTQ-Orbitrap. The
product-ion spectrum of the doubly charged molecular ion (dominant charge state) at m/z
781.336 shows a strong ion peak at m/z 732.1 which corresponds to the neutral loss of
H3PO4 from the parent ion. The fragment ions from Ser-Ser peptide bond cleavage are
missing due to the cyclo-elimination of H3PO4. The specific site of phosphorylation could
not be assigned from this approach. “p(SS)” indicates either serine residue may be
phosphorylated, “S*” indicates the thiocholine-modified site and “Nd” indicates the
deamidation of the asparagine residue.

Figure 2.11 Fragmentation of the thiocholine-modified peptide EIS*VADYTSHER
identified in PKA phosphorylated iPLA2β at both the MS2 and MS3 levels.
A. The product-ion spectrum of the triply charged molecular ion at m/z 536.933
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(EIS*VADYTSHER) was obtained with an ESI-LTQ-Orbitrap as described in the
Materials and Methods section. The fragment ion resulting from the neutral loss of
trimethylamine from the parent ion was not detected. Shown in the expanded spectrum
are examples of the diagnostic triad consisting of the y10+2 and b6+ fragmentation ions
resulting from peptide bond cleavage (m/z = 633.6 and 716.3) and further neutral loss of
trimethylamine (-59 Da, m/z = 603.3 and 657.2) or the thiocholine thiolate (-119 Da, m/z
= 574.1 and 597.2). “S*” indicates the thiocholine-modified site.
B. MS3 spectrum of the y10+2 ion at m/z 633.6 resulting from the fragmentation of the
triply charged molecular ion at m/z 536.933 (EIS*VADYTSHER) obtained with an
ESI-LTQ-Orbitrap as described in the Materials and Methods section. The ion peak at m/z
604.0 corresponds to the doubly charged fragment ion generated from the neutral loss of
trimethylamine from the parent ion y10+2.

Figure 2.12 Comparative quantification of phosphoproteins evaluated using β-casein
as a model protein.
Equal amounts of trypsinized β-Casein were modified with either “light” (12C,1H) or
“heavy” (13C,d3) thiocholine and mixed at a 1:1 ratio (v/v). The mixture was separated on
a reverse-phase C18 column and analyzed by an ESI-LTQ-Orbitrap as described in the
Materials and Methods section. The full mass spectrum of the modified peptides is shown
at the time of their co-elution. A doublet pattern of the peptides modified by “light” and
“heavy” thiocholine is evident. The ion intensity ratio of “light” vs. “heavy”
thiocholine-modified peptides obtained from full-mass spectra was 0.96±0.02 (average
73

adjusted ratio of five replicates with an expected ion intensity ratio of 1).
the

12

C,1H-thiocholine-modified site; “S**” indicates the

13

“S*” indicates

C,d3 thiocholine-modified

site.

Figure 2.13 Comparison of the retention time of the thiocholine(*) and
thiocholine-13C,d3(**)-modified

peptides

FQS*EEQQQTEDELQDK

and

FQS**EEQQQTEDELQDK from the model protein β-casein.
Two equal aliquots (1 and 2) of trypsinized β-casein were modified with thiocholine and
thiocholine-13C,d3 respectively as described in the Materials and Methods section.
Modified peptides of β-casein in aliquots 1 and 2 were then mixed at 1:1 (v:v; aliquot 1:
aliquot 2, or light: heavy). The mixture was analyzed with a reverse phase
HPLC-ESI-Orbitrap system as described in the Materials and Methods section. Shown
are the extracted ion chromatograms of the thiocholine and thiocholine-13C,d3-modified
peptides:

FQS*EEQQQTEDELQDK

(m/z

694.983;

dashed

line

“---”)

and

FQS**EEQQQTEDELQDK (m/z 696.323; solid line “—”). No chromatographic shift
was observed between light and heavy thiocholine-modified peptides. The light versus
heavy ratios (from data points A, B and C) are consistent at 0.96±0.02 with an expected
ratio of 1 during the elution of the peak.

74

Figure 2.1

75

Figure 2.2

76

Figure 2.3

77

Figure 2.4

78

Figure 2.5

79

Figure 2.6

80

81

82

Figure 2.7

83

84

Figure 2.8

85

Figure 2.9

86

Figure 2.10

87

88

Figure 2.11

89

90

Figure 2.12

Figure 2.13

91

CHAPTER 3

Identification of Endogenous Phosphorylation Sites of iPLA2β from Sf-9 Cells with
and Without Thiocholine Modification

3.1 Abstract

In the previous chapter, the chemical replacement of the phosphate on
phosphoserine and phosphothreonine residues via β-elimination and Michael addition
with thiocholine was identified as an effective strategy for the characterization of
phosphosites on model phosphoproteins. The increased ionization efficiency, improved
sensitivity and the generation of characteristic diagnostic triads of fragmentation ions
from signature neutral losses in tandem mass spectrometric analysis of thiocholine
derivatives markedly improved peptide identification. To demonstrate further the utility
of these procedures in living cells, BEMA with thiocholine was applied to identify the
endogenous phosphorylation sites of calcium-independent phospholipase A2β (iPLA2β)
heterologously expressed in Spodoptera frugiperda (Sf-9) cells. In parallel, traditional
direct analysis of phosphopeptides with data-dependent acquisition MS2 and neutral loss
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of phosphoric acid triggered MS3 was also performed to analyze iPLA2β phosphorylation.
The two methods were compared and evaluated to show that a total of 12 unique
phosphopeptides and 19 phosphorylation sites were identified using the thiocholine
BEMA strategy, whereas only five peptides and six phosphorylation sites on iPLA2β were
found with the traditional direct analysis. The larger number of phosphopeptides
identified with the BEMA method with thiocholine resulted in improved sequence
coverage compared to the traditional method. Finally, molecular modeling of iPLA2β was
performed with the I-TASSER server to reveal the close spatial proximity of the
phosphorylated residues to the catalytic site of the enzyme, suggesting the presence of
phosphorylation mediated regulation of iPLA2β.
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3.2 Introduction

Reversible phosphorylation on serine and threonine residues is regarded as one of
the most important molecular switches for the regulation of cellular signal transduction
pathways [1-3]. However, the intrinsic chemical properties of phosphorylated serine and
threonine-containing peptides hinder the detection and identification of phosphopeptides
as well as the exact localization of phosphorylated residues in mass spectrometric
analyses owing to poor ionization efficiency and subsequent low detection threshold.
Furthermore, the facile neutral loss of phosphoric acid through cyclo-elimination during
low-energy, collision-induced dissociation (CID) also contributes to the loss of
phosphoprotein sequence coverage [4-6].
As reported in Chapter 2, a novel strategy was developed to overcome these
hurdles for the sensitive detection and improved identification of pS/pT containing
peptides [7]. Briefly, thiocholine is introduced into the peptide at the phosphorylation site
via high-yield Ba2+ catalyzed β-elimination of phosphate and subsequent Michael
addition (Scheme 1.1). Sample complexity is reduced through reductive alkylation of
cysteines and development of optimized BEMA conditions for either pS or pT
individually. This charge-switch strategy results in much improved ionization efficiencies
during ESI with detection limits in the sub 500 amol/μL range. The sequence coverage of
the modified peptides is also increased owing to the higher charge states of
thiocholine-labeled tryptic peptides enabled by the endogenous positive charge on the
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quaternary amine. Phosphopeptide identification has been substantially improved by
exploiting the facile neutral loss of trimethylamine (m = 59 Da) and the thiocholine
thiolate (m = 119 Da) from the thiocholine adduct (Scheme 1.2) during MS2 and MS3
analyses.
To demonstrate further the utility of these procedures in the detection of proteins
phosphorylated in vivo, BEMA with thiocholine was applied to identify the endogenous
phosphorylation sites of the calcium-independent phospholipase A2β (iPLA2β)
heterologously expressed in Sf-9 cells. In parallel, traditional direct analysis of
phosphopeptides with data-dependent product-ion scan and neutral loss of phosphoric
acid triggered MS3 was also used for comparison with the current method. A total of 12
unique phosphopeptides and 19 phosphorylation sites were identified with the BEMA
strategy compared to five peptides and six phosphorylation sites with the traditional
method. The phosphopeptides identified with BEMA also showed better sequence
coverage and higher ion scores than the traditional method.
A 3-dimensional (3-D) model of iPLA2β was also derived with the I-TASSER
server [8-10]. All the phosphorylation sites identified either with BEMA with thiocholine
or the traditional direct analysis were placed in the 3-D model to reveal the potential
influence of these phosphorylated residues on the catalytic activity of the enzyme.
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3.3 Materials and Methods

Materials
POROS 20 R2 resin was purchased from ABI (Foster City, CA); Slide-A-Lyzer MINI
Dialysis Units, 7K MWCO were purchased from Pierce (Rockford, IL); Rapigest was
purchased from Waters (Milford, MA); trypsin was purchased from Promega (Madison,
WI); Solvents for mass spectrometric analyses were obtained from Honeywell
Burdick&Jackson (Muskegon, MI). Other chemicals were obtained from Sigma-Aldrich
(St. Louis, MO).

Synthesis of Thiocholine Chloride
Thiocholine chloride was prepared and the free thiol concentration of thiocholine
chloride was determined as previously described in Chapter 2.

Purification of Calcium-independent Phospholipase A2β from Sf-9 Cells
Hexahistidine tagged calcium-independent phospholipase A2β (iPLA2β) was expressed in
Sf9 cells and purified as previously described by Jenkins et al. [11]. Sf9 cells grown to a
density of 1 x 106 cells/mL were infected with a baculovirus encoding recombinant
iPLA2β with a C-terminal 6x His tag at an MOI of ~2 viral particles/cell. The cells were
incubated with constant agitation at 27 oC for 48 h. Next, cells suspended in the presence
of Trypan blue were inspected for evidence of infection (cell swelling, limited cell death).
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Infected cells were then centrifuged at 900 RPM for 10 min. The media was discarded
and the cells were resuspended in an equal volume Graces’s Insect Media without serum.
Cells were centrifuged again 900 RPM for 10 min and resuspended in 10% of the original
media volume of 25 mM potassium phosphate (pH 7.8) with 2 mM 2-mercaptoethanol,
and 20% glycerol with 5 µg/mL each of aprotinin and leupeptin. Cells were sonicated at
30% max power for 30 x 1 s bursts and centrifuged at 100,000 g for 1 h. The supernatant
was then applied to Co2+ metal affinity resin at 1mL resin per 200 mL original culture
volume pre-equilibrated with 25 mM potassium phosphate (pH 7.8) with 2 mM
2-mercaptoethanol, and 20% glycerol. The column was washed with 25 mM potassium
phosphate (pH 7.8) containing 2 mM 2-mercaptoethanol, 20% glycerol, and 5000 mM
NaCl. A continuous gradient of 0-200 mM imidazole over 20 column volumes was
employed to elute the bound iPLA2β(His)6. The fractions collected were tested for
phospholipase activity. Active fractions were pooled and applied to a 1 mL ATP agarose
pre-equilibrated with 20 mM imidazole (pH 7.6), 2mM 2-mercaptoethanol and 20%
glycerol. The column was next washed with 20 mM imidazole (pH 7.6) 2 mM
2-mercaptoethanol, and 20% glycerol with 150mM NaCl and 1 mM AMP. Bound
iPLA2β(His)6 was eluted with 20 mM imidazole (pH 7.6), 2 mM 2-mercaptoethanol and
20% glycerol with 150 mM NaCl, 5 mM ATP, in 1 mL fractions. All fractions were tested
for the phospholipase activity and the most active fractions were pooled together. The
protein concentration was determined using a Bradford assay [13].
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Tryptic Proteolysis of Calcium-independent Phospholipase A2β Prepared from Sf-9
Cells
The calcium-independent phospholipase A2β (iPLA2β) prepared from Sf-9 cells was
dialyzed against deionized water for 8 h using a Slide-A-Lyzer MINI Dialysis Unit, dried
in a SpeedVac apparatus (Savant, Holbrook, NY), and dissolved in 50 μL of 0.2%
Rapigest in 50 mM NH4HCO3. Next, 2.5 μL of 100 mM dithiothreitol (DTT) was added
to a final concentration of 5 mM. The sample was incubated at 60 °C for 30 min before 6
μL of 150 mM iodoacetamide was added to quench the reduction reaction and initiate
alkylation. The sample was incubated for an additional 30 min in the dark at room
temperature. Trypsin was added to the solution at a protease to protein ratio of 1:30 (w/w).
The total volume of the sample solution was adjusted to 100 μL with 50 mM NH4HCO3.
A total of 500 fmol/μL protein sample was incubated at 37 °C for 2 h and then acidified
with 10 μL of 10% TFA to lower the pH to < 2. The sample was again incubated at 37 °C
for 30 min and centrifuged at 13000 rpm to pellet the hydrolyzed Rapigest. Half of the
resultant supernatant was used for thiocholine modification while the rest of the sample
was subjected to MS analyses without modification.

BEMA of Trypsinized Calcium-independent Phospholipase A2β with Thiocholine
Half of the trypsinized iPLA2β sample was dried in a SpeedVac apparatus and
reconstituted in 50 μL deionized water followed by the addition of 38 μL DMSO and 12
μL of absolute ethanol. The trypsinized protein solution was then divided into 2 equal
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aliquots of 50 μL. The first aliquot was modified with a protocol optimized for pS
containing peptides and the second aliquot was modified with a protocol optimized for pT
containing peptides as follows: Aliquot 1 was mixed with 25 μL of freshly prepared
saturated Ba(OH)2. The reaction was incubated at room temperature under nitrogen for 1
h with gentle vortexing every 20 min. The final pH was 12~13. Next, 50 μL of 1 M
thiocholine solution freshly prepared in water was directly added to the reaction. The
reaction mixture was incubated at room temperature under nitrogen for 3 h at pH 8~9 and
then terminated by the addition of 5 μL of 10% TFA and the resultant solution was
desalted with a POROS 20 R2 microcolumn and dried. Aliquot 2 was mixed with 25 μL
of freshly prepared saturated Ba(OH)2. The reaction was incubated at room temperature
under nitrogen for 3 h with gentle vortexing every 20 min. The final pH was 12~13. Next,
the β-elimination reaction was terminated by addition of 10 μL of 10% TFA and the
resultant solution was desalted with a POROS 20 R2 micro column [12]. Briefly, a
POROS 20 R2 micro column was assembled by stamping out a small plug of C8 material
from a 3 M Empore C8 extraction disk using a HPLC syringe needle and placing this
plug in the constricted end of a GELoader tip. Next, POROS R2 beads that were
suspended 50% acetonitrile at 5mg/200 µL were packed in the GELoader tip by pressing
air through the micro column using an Eppendorf syringe. The length of the packed
POROS R2 resin was about 3~6 mm. Then the column was washed with 30 µL 50%
acetonitrile and equilibrated with 30 µL 0.1% trifluoroacetic acid. The sample solution
was then loaded onto the POROS R2 micro column. The sample was slowly passed
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through the micro column by pressing air through using a Eppendorf syringe. The column
was washed twice with 30 µL 0.1% trifluoroacetic acid and the bounded peptides were
eluted first using 30 µL 70% acetonitrile with 0.05 % trifluoroacetic acid, then 5 µL 30%
acetonitrile with 0.05% trifluoroacetic acid. The purified peptide solution was dried and
reconstituted in 50 μL of 0.5 M thiocholine solution freshly prepared in 0.1 M NaOH.
The mixture was incubated at 50 °C under nitrogen for 5 h at pH 8~9. The reaction was
terminated by the addition of 5 μL 10% TFA and the resultant solution was again desalted
with a POROS 20 R2 microcolumn and dried.

HPLC-ESI-MS2/MS3 Mass Spectrometric Analyses
The desalted and dried peptide samples were

reconstituted in 0.1% formic acid before

injection and separation using a Surveyor HPLC system (Autosampler and pump,
ThermoFisher, San Jose, CA) equipped with a reverse-phase C18 PepMap100 Nano-LC
column (75 μm I.D. × 15 cm, 3 μm, 100 Å; Dionex, Sunnyvale, CA). The flow rate was
maintained at 220−280 nL/min. Samples elut ing from the column were directed to the
nanospray apparatus (i.e., NanoMate HD with LC coupler, Advion Bioscience Ltd.,
Ithaca, NY) and sprayed directly into a linear ion trap in tandem with an Orbitrap
(LTQ-Orbitrap) mass spectrometer (ThermoFisher, San Jose, CA) at a spray voltage of
1.7 kV in the positive ion mode. iPLA2β samples, modified by the two optimized
protocols, were analyzed first in survey runs, which consisted of a 90 min gradient from
100% A to 50% A, 50% B (Buffer A: 90% water, 10% acetonitrile, 0.1% formic acid;
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Buffer B: 10% water, 90% acetonitrile, 0.1% formic acid, v:v)) and data-dependent MS2
analyses: full mass scans in the Orbitrap (300−1600 m/z, mass resolution = 30 000) were
followed by product-ion scans in the LTQ for the five most abundant ions. The ions of
interest from the survey runs were then included in the parent mass list of the target runs.
The target runs consisted of a 180 min gradient from 100% A to 75% A, 25% B (120 min),
then to 50% A, 50% B (60 min) and data-dependent MS2/MS3 analyses: full mass scans
in the Orbitrap (300−1600 m/z, mass resolution = 30 000) were followed by product-ion
scans in the LTQ of the three most abundant ions from the parent mass list and the MS3
scans in the LTQ of the 10 most intense fragment ions following each of the three
product-ion scans. A control unmodified trypsinized iPLA2β sample was analyzed using
the same survey run method as the thiocholine-modified samples. The target run for the
unmodified sample consisted of an inclusion list generated from the survey run, a 180
min gradient (100% A to 75% A, 25% B (120 min), then to 50% A, 50% B (60 min)), and
data-dependent MS2/MS3 analyses which consisted of an initial full mass scans in the
Orbitrap (300−1600 m/z, mass resolution = 30 000) followed by product-ion scans of the
five most abundant ions from the parent mass list with neutral loss of H3PO4 triggered
MS3 scans in the LTQ. The normalized collision energy for CID was set at 25 for all
data-dependent scans.

Data Processing
The local MASCOT server was used to conduct all database searches. A single-protein
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(iPLA2β) database was created by in silico trypsinolysis. Thiocholine with neutral losses
of trimethylamine and thiolate were integrated into MASCOT for customized processing
of

the

designed

covalent

modifications

for

serine

and

threonine

residues.

Carbamidomethylation of cysteine(C) residues was set as a fixed modification for the
trypsinized iPLA2β samples. Common variable modifications included N-terminal and
lysine acetylation (N-terminus, K), asparagine and glutamine deamidation (N,Q) and
methionine oxidation (M). A maximum of two missed cleavages were allowed. Full mass
and product-ion mass accuracy were set at 5 ppm and 1 Da, respectively. All
identifications by MASCOT were manually verified. All MS3 scans were analyzed
manually. The 3-D model of iPLA2β was generated by a web based program on the
I-TASSER server developed by Y. Zhang at the University of Michigan [8-10]. The
results are presented in the format of a PDB file visualized using ViewerLite freeware
and the distances between the amino acid residues were measured using the
“Monitor--Distance” feature included in the software.
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3.4 Results and Discussion

Calcium-independent phospholipase A2β (iPLA2β) belongs to the superfamily of
phospholipases A2 [14]. Phospholipases A2 catalyze the hydrolysis of phospholipids at the
sn-2 position to release fatty acids [15-16], such as arachidonic acids and
lysophospholipids, which are the precursors of multiple bioactive messengers [17-18].
According to their different properties, such as sequence homology, substrate selectivity,
subcellular location and dependence on calcium ion, phospholipases A2 can be grouped
into three categories: secretory phospholipases A2 (sPLA2s), cytosolic phospholipases A2
(cPLA2s) and calcium-independent phospholipases A2 (iPLA2s) [19-20]. Cytosolic
phospholipases A2 are important intracellular phospholipases whose members contain
(with the exception of cPLA2γ) a calcium-binding domain (C2), which upon binding Ca2+
results in their translocation from cytosol to intercellular membrane compartments to
hydrolyze their phospholipid substrates at the sn-2 position and release fatty acids [21].
The phosphorylation and Ca2+ mediated regulation of cPLA2α was extensively
studied [22-24]. The endogenous phosphorylation sites of cPLA2α heterologously
expressed in Sf-9 cells were previously identified as ser-437, ser-454, ser-505 and ser-727
by mass spectrometry and automated Edman sequencing [25]. Treatment of cPLA2α with
the phosphatase inhibitor okadaic acid resulted in a 4.5 fold increase in the
phosphorylation at serine 727 and an increased release of arachidonic acid. These results,
in

conjunction

with

previous
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studies

demonstrated

that

phosphorylation/dephosphorylation of cPLA2α is an important molecular mechanism
underlying the regulation of arachidonic acid release [25]. Similarly, iPLA2β is likely
regulated by phosphorylation/dephosphorylation mechanism, although current methods
have failed to identify specific residues whose phosphorylation correlate with alterations
in catalytic activity. Thus, it is of particular importance to gain insight into the
phosphorylation state of iPLA2β in vivo to provide a molecular foundation for further
investigation of the role of phosphorylation/dephosphorylation of iPLA2β in diverse
processes of substantial biologic significance such as cardiac function, arachidonic acid
release, cell proliferation and apoptosis [26-29]. A primary purpose of this study is to
compare the utility of the developed BEMA strategy with a traditional direct analysis
method in a system where the protein phosphorylation level is not artificially elevated.
Hexahistidine-tagged calcium-independent phospholipase A2β (iPLA2β) was
expressed in Sf9 cells and purified as previously described by Jenkins et al. [11]. Purified
iPLA2β was modified with thiocholine by using two separate protocols optimized for
either pS or pT-containing phosphopeptides. Modified and unmodified peptides were
analyzed with HPLC-ESI-MS2/MS3 as described in the Materials and Methods section.
As shown in Table 3.1, six different endogenous phosphorylated sites, originating
from five unique phosphopeptides, were identified in iPLA2β without thiocholine
modification using the traditional MS analysis strategy as described in the Materials and
Methods. No neutral loss of phosphoric acid triggered MS3 were obtained for any of the
identified peptides.
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Conversely, as shown in Table 3.2, with the β-elimination and Michael addition
strategy, a total of 19 different phosphorylated residues were identified. These
phosphorylation sites originated from 14 phosphopeptides. Identified peptides with
missed tryptic cleavages are listed together with the completely trypsinized peptides
indicated by bold-bordered boxes. The peptides contained within the bold-bordered boxes
are considered as one unique sequence. Thus, there are 12 unique phosphopeptides found
by the BEMA method. The phosphorylation sites listed in the table separated with a “/”
indicate that the monophosphopeptide has more than one non-concurrent phosphorylation
site. The product-ion spectra of all the peptides identified were verified manually, all of
which contained signature peaks generated by the neutral loss of trimethylamine and/or
thiocholine thiolate. As indicated in bold font in Table 3.1, 11 phosphopeptides from nine
unique sequences showed at least one dominant peak resulting from the neutral loss of
trimethylamine (-59 Da) at the level of MS3 analyses out of 14 phosphopeptides and 12
unique sequences.
The sequence coverage of the identified peptides was calculated using all b and y
ions present in the product-ion spectra over the number of all possible b and y ions. The
phosphopeptides identified with the BEMA strategy showed better sequence coverage
than those identified with the traditional method. Eleven out of 14 phosphopeptides
modified with thiocholine had sequence coverage greater than 50%; whereas three out of
five phosphopeptides without any modification identified with traditional mass
spectrometric methods showed sequence coverage above 50%.
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Figure 3.1-A shows the product-ion spectrum of the triply charged
thiocholine-modified peptide VKEIS*VADYTSHER (24−37). This spectrum consists of
b and y ions with diagnostic triads of all thiocholine containing peptidic fragment ions.
Shown in the expanded spectrum are the representative diagnostic triads from y12+2
fragment ions resulting from peptide bond cleavage (m/z = 754.7) and further neutral loss
of trimethylamine (-59 Da, m/z = 725.1) and the thiocholine thiolate (-119 Da, m/z =
695.2). Of the ions generated at MS2 level, the ten most abundant ions were chosen to be
further fragmented at the MS3 level. Examination of the y10+2 ion at m/z 633.5 (among the
top ten ions selected) demonstrated that it also possessed an intact thiocholine side chain,
which led to a signature neutral loss pattern in its MS3 spectrum (Figure 3.1-B). The ion
at m/z 603.9 is formed by the neutral loss of trimethylamine from the precursor y10+2 at
m/z 633.5.
The product-ion spectrum shown in Figure 3.2 is the triply charged peptide
VKEIpSVADYTSHERVR (24-39) identified with the traditional method, corresponding
to the phosphopeptide VKEIS*VADYTSHER (Figure 3.1-A) with one additional missed
cleavage. The spectrum provides minimal sequence informative ions in comparison to
that of the thiocholine-modified peptide with lower sequence coverage and a lower ion
score.
Examination of the fragmentation pattern of VKEIS*VADYTSHER demonstrated
that the thiocholine side chain enabled a unique tandem fragmentation pattern ideal for
proteomic analyses, since sequencing of the peptide at the MS2 level is not compromised
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by subsequent neutral losses but rather strengthened by the presence of diagnostic triads
of fragment ions in conjunction with the signature neutral loss at the MS3 level. As
previously discussed, one of the promising prospects of this approach is the use of these
unique and predictable diagnostic triads of fragmentation ions from thiocholine-modified
peptides in a weighted scoring system, where the intrinsic chemical properties of the
modified peptide could enhance identification of phosphorylated peptides and
phosphosites. Even though such a scoring system is not currently available, combining
the current MASCOT score with high mass accuracy ( < 5ppm) and the diagnostic triad
of fragment ions in both MS2 and MS3 levels will ensure the identification of the
modified peptides are made with high confidence.
To gain insight into the potential mechanistic significance of the identified
iPLA2β phosphosites, a three-dimensional model of iPLA2β was generated using the
I-TASSER server, an internet service that predicts protein structures and generates protein
3-D models [8-10]. The I-TASSER program was developed by Yang et al. at the
University of Michigan. 3D models are predicted based on multiple-threading alignments
generated by Local Meta-Threading-Server (LOMETS) that generates protein 3-D
models by collecting target-to-template alignments with high scores as well as iterative
TASSER simulations. The I-TASSER server was ranked as the No. 1 server with the best
global distance test total score (GDT-TS), which is a measure of the similarity between
two different protein structures with the same primary structure, but different tertiary
structures, in the server section of both the 7th and 8th CASPs (Critical Assessment of
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Techniques for Protein Structure Prediction). As shown in Figure 3.3-A, the catalytic
serine located within the lipase consensus sequence GXSXG resides within the central
catalytic core adjacent to the nucleotide binding motif (GXGXXG) (S465) [30]. All the
phosphorylation sites identified either with BEMA with thiocholine or through the
traditional direct analysis were located in the 3-D model. The distance (in Å) between
these phosphorylated serine/threonine residues and the active site of serine 465 measured
by using atom-to-atom distances between the hydroxyl oxygen of phosphorylated
serines/threonines residues and the hydroxyl oxygen of serine 465 are listed in Table 3.3.
The closest of the identified phosphorylated residues, threonine 521 is predicted to be at a
distance of 8.67 Å from the catalytic site in this model, which is also labeled in Figure
3.3-A. At this distance, the phosphorylation/dephosphorylation of threonine 521 could
significantly influence the catalytic activity of the enzyme.
Other phosphorylated serines/threonines within the catalytic core, labeled in
Figure 3.3-B, undergo phosphorylation/dephosphorylation that could also affect the
activity of iPLA2β. As shown in Figure 3.3-C, many of the observed phosphosites in
iPLA2β are located within the ankyrin repeat domain; these residues

likely facilitate

specific binding to protein partners in a phosphorylation-dependent fashion. The
phosphorylation/dephosphorylation cycling of these residues could impact the regulation
of protein-protein interactions during the binding of iPLA2β to cellular membranes that
contain ankyrin-binding proteins.
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3.5 Conclusion and Perspective

We demonstrated the utility of the β-elimination and Michael addition strategy in
the identification of endogenous phosphorylation sites of iPLA2β heterologously
expressed in Sf-9 cells. In comparison to the traditional direct mass spectrometric
analyses of phosphopeptides, the BEMA strategy identified more phosphopeptides with
more phosphorylation sites, and demonstrated improved sequence coverage and ion
scores. A diagnostic triad of fragment ions also facilitated improved phosphosite
determination at higher confidence levels of the peptides identified by MASCOT. The
3-D model of iPLA2β showed that threonine 521 was spatially the closest identified
phosphosite

to

serine

465

in

the

catalytic

domain.

The

phosphorylation/dephosphorylation of these sites likely affects the catalytic activity,
membrane binding and trafficking of iPLA2β.
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3.7 Table Legends

Table 3.1
Identification of endogenous phosphorylation sites in iPLA2β heterologously
expressed in Sf-9 cells without thiocholine modification.
Tryptic iPLA2β peptides were desalted, separated using reverse-phase nanobore HPLC,
and analyzed with an LTQ-Orbitrap system. Candidate peptides were identified using
MASCOT with the designated thiocholine modification as well as common amino acid
modifications as described in the Materials and Methods. A total of five unique
phosphopeptides and six different phosphorylated residues were identified. “p” denotes
identified phosphorylation sites; “(p)” denotes that more than one phosphorylation site
was identified in the same peptide. Those that were not concurrent are indicated by “/”.
The superscripts “ace”, “d”, and “o” denote the following modifications: acetylation
(N-terminus), deamidation (NQ), and oxidation (M), respectively. All cysteine residues
were carbamidomethylated.

Table 3.2
Identification of endogenous phosphorylation sites in iPLA2β heterologously
expressed in Sf-9 cells with thiocholine modification.
Tryptic iPLA2β peptides were modified with thiocholine using two different protocols
optimized for either phosphoserine or phosphothreonine as described in the Materials and
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Methods. The thiocholine-modified peptides were desalted, separated using reverse-phase
nanobore HPLC, and analyzed with an LTQ-Orbitrap system. Candidate peptides were
identified using MASCOT with the designated thiocholine modification as well as
common amino acid modifications as described in Materials and Methods. A total of 12
unique phosphopeptides and 19 different phosphorylated residues were identified. “*”
denotes identified phosphorylation sites; “(*)” denotes that more than one
phosphorylation site was identified in the same peptide. Those that were not concurrent
are indicated by “/”. The superscripts “d”, and “o” denote the following modifications:
deamidation (NQ) and oxidation (M), respectively. All cysteine residues were
carbamidomethylated. Identified peptides with missed cleavages are listed together with
the completely trypsinized peptides outlined by bold-bordered boxes. Peptides which
yielded a signature neutral loss pattern in MS3 are highlighted in bold.

Table 3.3
Calculated distances between the catalytic site serine 465 of iPLA2β and the
identified phosphorylation sites of iPLA2β heterologously expressed in Sf-9 cells
utilizing the BEMA strategy or traditional direct analysis in the 3-D model of
iPLA2β molecule generated by I-TASSER.
A 3-D model of iPLA2β was generated using the I-TASSER server. All the
phosphorylation sites identified either with β-elimination and Michael with thiocholine
addition (denoted as “BEMA” in the table) or the traditional direct mass spectrometric
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method (denoted as “Direct” in the table) were located in the 3-D model. The distance
between the identified phosphorylated residues and the catalytic site serine 465 are given
in Å. The distance measured is the atom-to-atom distance between the hydroxyl oxygen
of serine 465 and the hydroxyl oxygens of the phosphorylated serines/threonines.
Threonine 521 is the most proximal residue (8.67 Å) to the catalytic site in this model.
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Table 3.1
Sequence#

Sequence

24-39
208-218

VKEIpSVADYTSHERVR
ace
NApSAGLNQVNK

266-282
396-407
633-643

ace

Phosphorylation
Site
S28
S210

GCAEMIISMoDSpSQIHSK
QdLQdDLMPIpSRAR
LSIVV(p)SLGpTGR

S277
S404
S638/T641

5.7
16.3

Δm
(ppm)
-2.34
-2.59

6.34
8.15
22.87

1.23
-1.86
-3.39

Ion Score

Coverage%
63%
82%
35%
42%
91%

Table 3.2
Sequence#

Sequence

Phosphorylation
Site

Ion Score

Δm
(ppm)

Coverage%

24-37

VKEIS*VADYTS(*)HER

S28/S34

54.62

-2.02

86%

( )

26-37

EIS*VADYTS * HER

S28/S34

34.13

-2.52

92%

38-53
246-261
307-327
396-405

VREEGQLILFQNAS*NR
CNdVMGPSGFPIHT*AMK
GCDVDSTS*AAGNTALHVAVMoR
QdLQDLMPIS*R

S51
S252/S258
S314
S404

58.41
7.47
3.72
16.69

-1.06
-1.03
-0.98
-3.99

81%
75%
38%
70%

408-417

KPAFILS*S(*)MR

S414/S415

14.77

-1.36

70%

( )

408-420

KPAFILS*S * MRDEK

S414/S415

19.21

-2.71

69%

479-489
497-511
513-524

S*MAYMRGVYFR
GS*RPYES(*)GPLEEFLK
EFGEHTKMoT*DVK

S479
S498/S503
T521

9.31
33.45
9.85

-3.31
-1.66
0.72

45%
80%
42%

528-537
582-595
694-705

VMLT*GT(*)LS(*)DR
SS*GAAPT(*)YFRPNdGR
AWS*EMVGIQYFR

T531/T533/S535
S583/T588
S696

33.06
29.26
34.15

-1.68
-1.14
-1.51

90%
71%
92%
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Table 3.3
Residue number

Identification Method

Distance to Serine 465 (Å)

Serine 28

BEMA/Direct

35.88

Serine 34

BEMA

33.99

Serine 51

BEMA

45.80

Serine 210

Direct

49.78

Serine 252

BEMA

43.60

Serine 258

BEMA

39.18

Serine 277

Direct

48.68

Serine 314

BEMA

45.88

Serine 404

BEMA/Direct

56.62

Serine 414

BEMA

54.70

Serine 415

BEMA

50.77

Serine 479

BEMA

27.49

Serine 498

BEMA

27.53

Serine 503

BEMA

26.44

Threonine 521

BEMA

8.67

Threonine 531

BEMA

17.09

Threonine 533

BEMA

17.66

Serine 535

BEMA

22.70

Serine 583

BEMA

25.98

Threonine 588

BEMA

26.00

Serine 638

Direct

34.45

Threonine 641

Direct

27.08

Serine 696

BEMA

43.57
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3.8 Figure Legends

Figure

3.1

Fragmentation

of

the

thiocholine-modified

peptide

VKEIS*VADYTSHER identified in iPLA2β at both the MS2 and MS3 levels.
A. The product-ion spectrum of the triply charged molecular ion at m/z 578.966
(VKEIS*VADYTSHER) was obtained with an ESI-LTQ-Orbitrap as described in
the Materials and Methods. The fragment ion resulting from the neutral loss of
trimethylamine from the parent ion was present at m/z 559.5. Shown in the expanded
spectrum (relative intensity zoom = 24%) are examples of the diagnostic triad consisting
of the y12+2 fragmentation ions resulting from peptide bond cleavage (m/z = 754.7) and
further neutral loss of trimethylamine (-59 Da, m/z = 725.1) or the thiocholine thiolate
(-119 Da, m/z = 695.2). Also shown is the y11+2 (m/z = 690.1) and its corresponding ion
peak of the neutral loss of trimethylamine (-59 Da) at m/z = 660.5. “S*” indicates the
thiocholine-modified site.
B. The MS3 spectrum of the y10+2 ion at m/z 633.5 resulting from the fragmentation of the
triply charged molecular ion at m/z578.966 (VKEIS*VADYTSHER) obtained with an
ESI-LTQ-Orbitrap as described in the Materials and Methods section. The ion peak
at m/z 603.9 corresponds to the doubly charged fragment ion generated from the neutral
loss of trimethylamine from the parent ion y10+2.
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Figure 3.2 Fragmentation of the phosphopeptide VKEIpSVADYTSHERVR
identified in iPLA2β without thiocholine modification.
The product-ion spectrum of the triply charged molecular ion at m/z 656.988
(VKEIpSVADYTSHERVR) was obtained with an ESI-LTQ-Orbitrap as described in
the Materials and Methods section. The fragment ion resulting from the neutral loss of
H3PO4 from the parent ion was not observed. “pS” indicates the phosphorylated site.

Figure 3.3 3-D model of iPLA2β generated by the I-TASSER server.
The primary amino acid sequence file of iPLA2β was submitted to I-TASSER server
located at http://zhanglab.ccmb.med.umich.edu/I-TASSER/. The 3-D model in PDB
format was generated and displayed with ViewerLite freeware.
A. The catalytic site serine 465 and phosphorylated residue threonine 521 are labeled.
The atom-to-atom distance between the hydroxyl oxygen of serine 465 and the hydroxyl
oxygen of the threonine 521 is calculated to be 8.67 Å in this model.
B. Phosphorylated residues within the catalytic core are labeled as follows: serine 28,
serine 34, serine 51, serine 210, serine 252, serine 258, serine 277, serine 314, serine 304,
serine 414, and serine 415.
C. Phosphorylated residues within the ankyrin domain of iPLA2β are labeled as follows:
serine 479, serine 498, serine 503, threonine 521, threonine 531, threonine 533, serine
535, serine 583, threonine 588, serine 638, threonine 641, and serine 696.
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CHAPTER 4

Quantitative Analysis of Alterations in the Myocardial Mitochondrial
Phosphoproteome Induced by Cardiac Ischemia Assessed using β-Elimination and
Michael Addition with Light and Heavy Thiocholine

4.1 Abstract

Quantitative analysis of alterations in the murine myocardial mitochondrial
phosphoproteome induced by global cardiac ischemia was performed using the developed
mass spectrometric strategy of β-elimination of phosphate and subsequent Michael
addition (BEMA) with natural abundance (light) thiocholine and stable-isotope labeled
(heavy) thiocholine. The developed strategy exploited the increased ionization efficiency,
sensitivity and diagnostic triads of fragmentation ions to identify 141 phosphopeptides
from 133 distinct proteins that include the identification of 36 phosphopeptides from 35
mitochondrial proteins containing 37 previously unreported mitochondrial phosphosites.
The identities of these novel phosphosites were first determined using the MASCOT
search engine and were substantiated through rescoring using the Percolator algorithm.
Quantitation of alterations in mitochondrial protein phosphorylation resulting from
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cardiac ischemia were achieved by comparing phosphopeptides modified by heavy
thiocholine obtained from mitochondria in ischemic hearts (i.e., global ischemia) to those
modified by light thiocholine in control hearts ( i.e., normal flow perfusion). Collectively,
these results demonstrate that β-elimination of phosphate and subsequent Michael
addition (BEMA) using light and heavy thiocholine represent an effective massspectrometry-based strategy for comparative quantitative phosphoproteomics in whole
organ systems during pathophysiologic perturbations.
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4.2 Introduction

The reversible protein phosphorylation and dephosphorylation of serine and threonine
residues are the most ubiquitous posttranslational modifications that regulate critical
signaling pathways in eukaryotic cells [1-3]. As in most biologic systems, protein
phosphorylation plays multiple roles in regulating a diverse array of mitochondrial
functions. Prior work demonstrated that numerous proteins are phosphorylated in the
mitochondria of yeast [4], mouse liver [5], mouse brain [6], bovine heart [7], and in
virtually every cell type and organ system studied [8-9]. In mitochondria, it is well
established that the activities of enzymes, such as pyruvate dehydrogenase [10-14] and
cytochrome oxidase [15-16] are regulated by reversible protein phosphorylation that
contributes to cellular bioenergetics, substrate utilization and the deleterious sequelae of
oxidative

stress.

However,

a

quantitative

mass

spectrometric

approach

for

phosphoproteome analysis on a global scale identifying the number and magnitude of
alterations in the phosphorylation at specific phosphosites of mitochondrial proteins after
pathophysiologic perturbations has not been well defined.
Radiolabeling of biologic tissues with [γ-32P]-ATP is a traditional quantitative
approach that has been used to provide early insights into the mitochondrial
phosphoproteome [8, 17]. Radiolabeling is a very sensitive technique for the detection of
phosphoproteins and the characterization of overall changes in the level of protein
phosphorylation. However, its utility is limited by its inability to localize readily the
phosphosite without additional approaches such as site-directed mutagenesis, enrichment
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processes, or Edman degradation. Although fluorescence labeling represents a sensitive
nonradioactive alternative to

32

P radiolabeling [7] it suffers multiple limitations because

fluorescence labeling alone cannot provide primary sequence information of the
phosphorylated peptide or its phosphosite. Meanwhile, mass spectrometric approaches
for phosphoproteome analysis are complicated by facile cyclo-elimination of phosphoric
acid, resulting in ambiguities in phosphosite assignment and poor ionization efficiencies
of phosphopeptides rendering their detection difficult. Thus, these techniques are not
amenable to high-throughput quantitative analysis required for comprehensive
phosphoproteome determination. [18].
Isobaric tags for relative and absolute quantitation (iTRAQ) is an effective massspectrometry-based labeling technique for multiplexed quantitative phosphoproteomics
[19-21]. For this approach, tryptic peptides from proteins of different biological states are
modified with different isobaric tags. The same phosphopeptides from different states are
identical in the full-mass scan but can produce unique reporter ions during the tandem
mass spectrometric analysis, thus providing information of comparative quantitation
based on the relative abundances of the reporter ions. However, given that quantitation is
achieved at the MS2 level, the sensitivity of this strategy is limited and could lead to large
run-to-run deviations and, thus, poor reproducibility.
Previously, we developed a sensitive method taking advantage of the unique
chemistry of the quaternary amine to enhance ionization efficiency in conjunction with
the strong nucleophilicity of the thiol present in thiocholine to effect the BEMA strategy
with thiocholine as the Michael donor (as described in Chapter 2). This strategy results in
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marked increase in ionization sensitivity during ESI accompanied by increased sequence
coverage in model compounds as described in Chapters 2 and 3. More specifically, the
definitive localization of phosphorylated residues is greatly facilitated by the thiocholine
side chain through the generation of diagnostic triads of fragment ions resulting from
peptide bond cleavage and further neutral loss of either trimethylamine (-59 Da/-63 Da)
or thiocholine thiolate (-119 Da/-123 Da) during CID in MS2 and MS3experiments.
Through utilization of titanium dioxide resin (TiO2) for phosphopeptide enrichment,
sample complexity is greatly reduced [23] leading to improved chromatographic
coverage of the phosphopeptides of interest. To minimize false discovery rates, all
database searches generated by MASCOT [24] were re-scored by Percolator [25-26], a
semi-supervised machine learning algorithm further substantiating the identification of
the observed phosphosites.
In this study, we successfully identified 141 phosphopeptides from 133 unique
proteins with 228 phosphorylation sites from six independent biological replicates
generated from 24 perfused mouse hearts (12 control-perfused, 12 global ischemic).
Importantly, these data included 36 phosphopeptides from 35 mitochondrial proteins with
50 phosphosites, 37 of which are new mitochondrial phosphosites that have not been
reported previously. Relative alterations in the magnitude of phosphorylation were
evaluated for all phosphopeptides identified in three independent replicate samples using
relative molecular ion peak intensity ratios. This study has demonstrated that βelimination of phosphate and subsequent Michael addition (BEMA) using light and
heavy thiocholine represents an effective mass-spectrometry based strategy for
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comparative quantitative phosphoproteome analyses of intact organs subjected to
pathologic perturbations.
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4.3 Materials and Methods

Materials
Rapigest was purchased from Waters (Milford, MA); Protein concentrations or amounts
were determined using a BCA protein assay kit was purchased from Pierce (Rockford,
IL); trypsin was purchased from Promega (Madison, MI); Titansphere Titanium dioxide
resin was purchased from GL Sciences (Torrance, CA); POROS 20 R2 resin was
purchased from ABI (Foster City, CA). All solvents for mass spectrometric analyses were
obtained from Honeywell Burdick&Jackson (Muskegon, MI); all other chemicals were
obtained from Sigma-Aldrich (St. Louis, MO)

Synthesis of Thiocholine Chloride (Light) and Thiocholine-13C,d3 Chloride (Heavy)
Thiocholine chloride was prepared and the free thiol concentration of thiocholine
chloride was determined as previously described in Chapter 2.

Perfusion of Isolated Langendorff Mouse Hearts
Animal protocols used were in strict accordance with the National Institutes of Health
guidelines for humane treatment of animals and were reviewed and approved by the
Animal Care Committee of Washington University. Mouse hearts were either perfused
normally as controls or subjected to global ischemia, as previously described [28]. Briefly,
mice were anesthetized with sodium pentobarbital and their hearts were excised and
immersed in oxygenated Krebs-Henseleit buffer containing : 137 mM NaCl, 4.7 mM KCl,
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1.2 mM MgSO4, 1.2 mM KH2PO4, 15 mM NaHCO3, 3mM CaCl2, 0.5 mM NaEDTA and
11mM glucose equilibrated with O2/CO2 (95:5), plus insulin (70 mU/L) and BSA (2.8%),
at 37 °C. Mouse hearts were then perfused by retrograde aortic flow with oxygenated
buffer at 37 °C. Perfusion pressures were maintained constant at 45 to 50 mm Hg. All
hearts were initially perfused with oxygenated buffer for a 15-minute equilibration period.
12 mouse hearts were perfused with oxygenated buffer for an additional 30 mins and
served as controls. Another 12 mouse hearts were subjected to global ischemia for an
additional 30 min.

Preparation of Mouse Mitochondria
Mitochondria were prepared as previously described with minor modifications [29-30].
Each perfused heart prepared as described above was immediately placed at 10% (w/v) in
ice-cold pH 7.4 HEPES buffer containing 1 mM EDTA, 250 mM sucrose, phosphatase
inhibitor cocktail (1 (Sigma) at a 100-fold dilution) and a customized phosphatase
inhibitor cocktail (10 mM sodium fluoride, 4 mM sodium tartrate, 2 mM βglycerophosphate, 2 mM sodium pyrophosphate). Hearts tissues were homogenized with
a glass dounce homogenizer, centrifuged at 700 g for 10 min and the supernatant was
collected. Next, the supernatant was centrifuged at 10,000 g for 15 min to pellet
mitochondria. Mitochondria from two control hearts were pooled together to give six
individual control samples while the same was done for the ischemic samples. All control
and ischemic samples were processed using the same protocol except that light
thiocholine was used for control hearts and heavy thiocholine was utilized for ischemic
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hearts for the Michael addition reaction.

Tryptic Proteolysis of Mitochondrial Proteins
Mitochondria were re-suspended in 750 µL of 80% aqueous methanol solution in a 1.5mL micro centrifuge tube and mitochondrial proteins were precipitated as previously
described [31]. Briefly, 150 µL of CHCl3 was added to the above mitochondrial
suspension and vortexed, followed by the addition of 450 µL of H2O. The mixture was
vortexed again before centrifugation at 14,000 g for 15 min, separated into two layers,
and the protein located at the interface appeared as a white layer. The upper layer
(methanol and H2O) was removed and another 450 µL of methanol was added. The
sample was vortexed and centrifuged at 14,000 g for 10 min. The protein pelleted at the
bottom of the tube was air-dried and re-suspended in 1000 µL of 0.2% Rapigest in 50
mM NH4HCO3 and incubated at 100 °C for 5 min. Protein content was determined using
the micro-BCA protein assay kit (Pierce). 1 mg of total protein from each sample was
used for subsequent preparations. The volume of each sample was adjusted to 1 mL using
50 mM NH4HCO3. Next, 52 µL of 100 mM dithiothreitol (DTT) was added to a final
concentration of 5 mM. The sample was incubated at 60 °C for 30 min before 120 µL of
150 mM iodoacetamide was added to quench the reduction reaction and initiate
alkylation. The sample was incubated for an additional 30 min in the dark. Trypsin was
added to the solution at a protease to protein ratio of 1:30 (w/w). The solution was
incubated at 37 °C overnight. The pH of the solution was lowered to < 2 to terminate the
digestion and the incubated at 37 °C for 30 min. Hydrolyzed Rapigest was pelleted by
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centrifugation at 13, 000 rpm.

Highly Selective Enrichment of Phosphorylated Peptides by Titanium Dioxide (TiO2)
Micro Column Chromatography
Trypsinized protein samples were dried in a SpeedVac apparatus (Savant, Holbrook, NY),
and reconstituted in 280 mg/mL 2,5-Dihydroxybenzoic acid (2,5-DHB) in 60%
acetonitrile (ACN), 1.5% Trifluoroacetic acid (TFA). Phosphorylated peptides in the
trypsinized samples were enriched using TiO2 micro columns as previously described
with minor modifications [32]. Bound phosphorylated peptides were eluted twice with 40
µL 25% ammonium hydroxide (pH > 10.5) and once with 30 µL 30% ACN. The fractions
containing the eluted phosphopeptides were acidified by the addition of 15 µL 90%
formic acid. 30 µL of water was added to reduce the organic solvent concentration to <
5%.

BEMA of Phosphorylated Peptides Enriched by TiO2 Micro Column Chromatography
with Light and Heavy Thiocholine
Phosphorylated peptides eluted from the TiO2 micro columns were desalted using
POROS 20 R2 micro columns as previously described [33]. Briefly, a POROS 20 R2
micro column was assembled by stamping out a small plug of C8 material from a 3M
Empore C8 extraction disk using a HPLC syringe needle and placing this plug in the
constricted end of a GELoader tip. Next, POROS R2 beads that were suspended in 50%
acetonitrile at 5 mg/200 µL were packed into the GELoader tip by pressing air through
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the micro column using an Eppendorf syringe. The length of the packed POROS R2 resin
was about 3-6 mm. The column was then washed with 30 µL 50% acetonitrile and
equilibrated with 30 µL 0.1% trifluoroacetic acid. Samples containing the
phosphopeptides were then loaded onto the POROS R2 micro column. The sample was
slowly passed through the micro column with compressed air from the Eppendorf syringe.
The column was washed twice with 30 µL of 0.1% trifluoroacetic acid and the bound
peptides were eluted first using 30 µL of 70% acetonitrile containing 0.05 %
trifluoroacetic acid, then 5 µL of 30% acetonitrile containing 0.05% trifluoroacetic acid.
The desalted phosphorylated peptides were dried in a SpeedVac apparatus and
reconstituted in 50 µL deionized water followed by the addition of 38 µL DMSO and 12
µL of absolute ethanol. 25 µL of freshly prepared saturated Ba(OH)2 was then added to
the peptide solution to start the β-elimination reaction. After incubation at room
temperature under nitrogen for 3 h with gentle vortexing every 20 min. The final pH was
12~13. 50 µL of 1 M thiocholine chloride was added to each of the six the control
samples and 50 µL of 1 M thiocholine-13C,d3 chloride was added to each of the six the
ischemic samples. The reaction mixture was incubated at room temperature under
nitrogen for 5 h at pH 8~9 and then terminated by the addition of 5 µL of 10% TFA.

HPLC-ESI-MS2/MS3 Mass Spectrometric Analyses
Six control and six ischemic samples modified by light and heavy thiocholine
respectively were randomly pooled in pairs to give six mixed samples for six individual
replicates. The mixed samples were then desalted with POROS 20 R2 micro columns,
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dried and reconstituted in 0.1% formic acid before injection and separation using a
Surveyor HPLC system (Autosampler and pump, ThermoFisher, San Jose, CA) equipped
with a reverse-phase C18 PepMap100 Nano-LC column (75 µm I.D. × 15 cm, 3 µm, 100
Å; Dionex, Sunnyvale, CA). The flow rate was maintained at 220
−280 nL/min. Samples
eluting from the column were directed to the nanospray apparatus (i.e., NanoMate HD
with LC coupler, Advion Bioscience Ltd., Ithaca, NY) and sprayed directly into a linear
ion trap in tandem with an Orbitrap (LTQ-Orbitrap) mass spectrometer (ThermoFisher,
San Jose, CA) at a spray voltage of 1.7 kV in the positive ion mode. Each of the six
replicates was analyzed first in a survey run, which consisted of a 180 min gradient from
100% A to 75% A, 25% B (Buffer A: 90% water, 10% acetonitrile, 0.1% formic acid;
Buffer B: 10% water, 90% acetonitrile, 0.1% formic acid, v:v) for 120 min, then to 50%
A, 50% B (60 min). For data-dependent MS2 analyses, full mass scans in the Orbitrap
(300−1600 m/z, mass resolution = 30 000) were followed by product-ion scans in the LTQ
of the five most abundant ions. These ions of interest generated from the survey run were
then included in the parent mass list of a target run. The target run was conducted
essentially the same as the survey run except that during the MS2 data-dependent
analyses, the five most abundant ions from the parent mass list were fragmented. A third
run was conducted for MS3 analyses. It consisted of a 180 min gradient from 100% A to
75% A, 25% B (120 min), then to 50% A, 50% B (60 min) for data-dependent MS2/MS3
analyses in which full mass scans in the Orbitrap (300
−1600

m/z, mass resolution = 30

000) were followed by product-ion scans in the LTQ of the three most abundant ions
from the parent mass list and the MS3 scans in the LTQ of the ten most abundant
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fragment ions following each of the three product-ion scans.

MASCOT Database Search
The local MASCOT server (version 2.1.1) with an up-to-date IPI mouse database was
used to conduct all database searches [24]. The “auto decoy” option was chosen. Light
and heavy thiocholine with neutral losses of trimethylamine and thiolate were integrated
into MASCOT for customized processing of the designed covalent modifications for
serine and threonine residues. Carbamidomethylation (C) was set as the fixed
modification. Common variable modifications included acetylation (N-terminus, K),
deamidation (NQ) and oxidation (M). A maximum of two missed cleavages were allowed.
Full mass and product-ion mass accuracy were set at 5 ppm and 1 Da respectively.
Database searches were conducted using an automatic decoy database provided by the
local MASCOT server.

Post-MASCOT Processing using Percolator
All MASCOT search results were re-scored and re-ranked by a stand-alone version of the
MASCOT Percolator [25-26]. All the programs utilized were downloaded using links
from http://www.sanger.ac.uk/resources/software/mascotpercolator. Since the MASCOT
searches were conducted using the option of “auto decoy”, the target and decoy
MASCOT result files (.DAT) required by the Percolator program were the same. The
“rankdelta N” value was set at default = “1”, indicating all peptide hit ranks that have a
delta score of < 1 relative to the top hit match were processed. The false discovery rate
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(FDR) was set at 1%. Peptide hits with a posterior error probability (PEP) value < 0.05
(score > 13) were considered automatic positive identifications. Peptides originating from
mitochondrial proteins with a PEP > 0.05 but < 0.2 (7 < score < 13) were verified
manually for false identifications. All MS3 scans were analyzed manually for the
signature neural loss of trimethylamine (-59 Da/-63 Da).

Comparative Quantitation of Light and Heavy Thiocholine-Modified Peptides
Relative changes in phosphorylation state were evaluated for all phosphopeptides
identified in three or more independent replicate samples using relative peak intensity
ratios of the molecular ions of light and heavy thiocholine-modified peptides at the time
of their co-elution. The relative ratio was calculated by dividing the light peak intensity
by the heavy peak intensity. Dixon's Q [34] test was used to eliminate outlier(s) with 95%
confidence prior to calculations of sample average and standard deviation. The
subcellular locations of the phosphoproteins identified were determined using the protein
database UniProt [35-36] and LOCATE database [37-38].
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4.4 Results and Discussion

In this study, the phosphoproteome of mitochondria isolated from Langendorffperfused mouse hearts subjected to global ischemia was investigated. During prolonged
ischemia, flux through the mitochondrial electron transport chain (ETC) is attenuated
owing to the accumulation of reducing equivalents in the mitochondrial matrix in the
absence of oxygen. This results in the dramatic reduction of ATP production because
during ischemia, the redox reactions involving oxygen become the rate limiting steps for
the production of ATP. This ultimately leads to profound decreases in cellular ATP,
resulting in hemodynamic dysfunction [39-42]. The chain of signaling events in response
to the depletion of oxygen is regulated, at least in part, by changes in protein
phosphorylation [43-46]. However, the role of alterations in mitochondrial protein
phosphorylation in this process is at its early stages of understanding. Specifically, the
identity of the mitochondrial phosphoproteins and their specific phosphosites during
ischemia are largely unknown. Accordingly, we sought to determine specifically changes
in

protein

phosphorylation

following

myocardial

ischemia

using

quantitative

phosphoproteomics to gain insight into the signaling pathways and molecular
mechanisms that are activated during myocardial ischemia and result in alterations in
mitochondrial bioenergetics and signaling.
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Comparative Quantitative Phosphoproteomics using β-Elimination and Michael
Addition with Light and Heavy Thiocholine
As reported in Chapters 2 and 3, β-elimination of phosphate and subsequent Michael
addition (BEMA) with light and heavy thiocholine as the Michael donors is a sensitive
and effective strategy for the detection, identification, and quantitation of phosphoserine
and phosphothreonine residues. The overall workflow based on BEMA with light and
heavy thiocholine for the comparative quantitative phosphoproteomics of mitochondria
from mouse hearts upon induction of cardiac ischemia is detailed in Figure 4.1.
Mitochondria were isolated from both normally perfused and globally ischemic mouse
hearts by differential centrifugation. Mitochondrial proteins were then isolated by
methanol/chloroform precipitation, reconstituted in 0.2% Rapigest, and total protein
content was determined using a BCA protein assay. Next, 1 mg of protein from each
sample was subjected to trypsinolysis. The resultant tryptic peptides were affinity
purified using a TiO2 micro column for the selective enrichment of phosphopeptides. The
affinity purified phosphopeptides were desalted and modified with either light thiocholine
(control samples) or heavy thiocholine (ischemic samples). After the reactions were
terminated, control and ischemic samples were mixed together, desalted and analyzed by
using LC-MS/MS. The mass spectrometric data was searched by using MASCOT and rescored by Percolator to identify phosphopeptides. Quantitative information was obtained
from the relative peak intensity of the molecular ions of the phosphopeptides modified by
light and heavy thiocholine, respectively. The subcellular localization of the identified
proteins was determined using UniProt [35-36] and LOCATE [37-38] databases. Our
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strategy emphasized the rapid purification of mitochondrial to prevent intrapreparative
artifacts, recognizing that all mitochondrial preparations contain mitochondria-associated
proteins.
Mass spectrometric analysis of BEMA thiocholine-modified samples of mitochondria
from control and ischemic murine myocardium showed multiple ions which were
identified by sequential MASCOT and Percolator. The total ion chromatography (TIC)
obtained from a representative sample is shown in Figure 4.2-A. The extracted ion
chromatography (XIC) of the full-mass scans is presented in Figure 4.2-B.
A representative example of the diagnostic triad present in thiocholine-modified
peptides is shown in Figure 4.3-A. The product-ion spectrum of the quadruply charged
molecular

ion

at m/z 425.200

of

the

heavy

thiocholine-modified

peptide

YHGHS*MSDPGVSYR was identified as originating from the pyruvate dehydrogenase
E1 component subunit α. The spectrum shows the peptide bond cleavage fragment ions
B8+2 at m/z 510.9, B10+2 at m/z 588.2, B11+2 at m/z 637.5, B12+3 at m/z 454.6 and A11+3 at
m/z 416.2 (all fragment ions resulting from heavy thiocholine-modified peptides are
presented in capital letters, such as B, A). Also shown in the spectrum are representative
diagnostic triads consisting of the B10+2 fragmentation ions resulting from peptide bond
cleavage (to give an ion at m/z = 510.9) and further neutral loss of 13C,d3-trimethylamine
(-63 Da, m/z = 556.8) or the
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C,d3-thiocholine thiolate (-123 Da, m/z = 526.7). Figure

4.3-B displays the expanded product-ion spectrum of the quadruply charged molecular
ion modified by heavy thiocholine at m/z 425.200 (YHGHS*MSDPGVSYR) ranging
from m/z 380 to m/z 640. The spectrum shows that the heavy thiocholine-containing B
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ions are accompanied by the corresponding light thiocholine-containing b ions (all
fragment ions resulting from light thiocholine-modified peptides are presented in lowercase letters) resulting from the fragmentation of the light thiocholine-modified molecular
ion at m/z 424.195 (YHGHS*MSDPGVSYR): B8+2 at m/z 510.9 with b8+2 at m/z 509.0,
B10+2 at m/z 588.2 with b10+2 at m/z 586.2, B11+2 at m/z 637.5 with b11+2 at m/z 635.7, B12+3
at m/z 454.6 with b12+3 at m/z 453.3 and B10+3 at m/z 392.6 with b10+3 at m/z 390.5. This
indicates that during the data-dependent analysis both the light and heavy thiocholinemodified peptides were included for collision induced dissociation (CID). Given that the
structures of the peptides are identical, they produced the same corresponding B/b ions in
the Product-ion spectrum as indicated by the presence of multiple doublets. This is due to
the low-resolution capability of the linear ion trap when selecting the ion of interest for
fragmentation. With molecular mass 4 Da apart, both light and heavy thiocholinemodified peptides were included in the mass selection window at +4. The doublets of
peptide bond cleavage fragment ions resulting from light and heavy thiocholine-modified
peptides further confirm the identification of the peptide, the localization of the modified
residue(s), and the phosphorylation site(s). The relative peak intensities of the doublets
also serve as a redundant confirmation for the comparative quantitation conducted at the
molecular level.

Figure 4.3-C, D, E and F illustrate

fragmentation pattern (loss of

13

the signature neutral loss

C,d3-trimethylamine, -63 Da) at the MS3 level of the

heavy thiocholine containing fragment ions resulting from the peptide bond cleavages of
the quadruply charged molecular ion modified by heavy thiocholine at m/z 425.200
(YHGHS*MSDPGVSYR). In Figure 4.3-C, B11 - 63+2 at m/z 606.1 is the dominant
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neutral loss ion; in Figure 4.3-D, B10 - 63+2 at m/z 566.6 is the dominant neutral loss ion;
in Figure 4.3-E, B8 - 63+2 at m/z 479.5 is the dominant neutral loss ion; in Figure 4.3-F,
B12 - 63+3 at m/z 433.6 is the dominant neutral loss ion.
Collectively, the BEMA with light and heavy thiocholine strategy provides a rich
repertoire of information at the MS2 and MS3 levels that not only reveals the
identification of the modified phosphopeptide, and the localization of thiocholine
modification (phosphorylation), but also provides redundant comparative quantitative
information at MS2 level.

Improved MASCOT Results using the Post-Processing algorithm Percolator
MASCOT is one of the most widely used database search engines for the
identification of proteins and peptides based on tandem mass spectrometric data [24].
MASCOT employs an algorithm that ranks the correlation between the experimental
product-ion spectra and calculated peptide spectra based on the peptide sequences
included in the protein database. The correlation between an experimental and a
calculated spectrum is expressed by a score called peptide spectrum match (PSM).
However, the ranking based on PSMs does not constitute formal proof of the peptide of
interest in all cases. To substantiate results from MASCOT, the strategy of using decoy
protein databases that randomize and reverse the protein sequences in the original
databases [47-48] enabled the evaluation of peptide identifications using PSMs resulting
from both original and decoy databases, thereby allowing the subsequent detection of
false positives to determine the false discovery rate (FDR) [49]. MASCOT identifies
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peptides based on the comparison between the PSM of each mass spectrum and a
probability-based peptide identity score. If a PSM exceeds the threshold, the peptide
identification is a true identification with a certain confidence interval (e.g., a value of 95%
confidence is typically used). In addition, a second measurement of experimental vs.
calculated spectra is the peptide homology threshold. If the PSM is lower than the
homology threshold, it is considered an outlier [50]. As shown in Table 4.1, use of the
decoy database in combination with identity and homology thresholds, the performance
of MASCOT is not ideal, generating a FDR of over 11% FDR in each of the six
individual samples, and an overall FDR of 12.49%. Therefore, the Percolator algorithm
was employed to decrease the FDR obtained from MASCOT analysis alone. Percolator
utilizes a semi-supervised machine-learning based algorithm called support vector
machine (SVM) to compare the identifications resulting from the target and decoy
databases using MASCOT [25-26]. The detailed workflow of the algorithm of Percolator
is illustrated in Figure 4.4 (reproduced with permission from Figure 1 of the original
publication (Journal of Proteome Research, 2009, 8, 3176-3181 by M, Brosch, L. Yu, T.
Hubbard, and J. Choudhary)). All MASCOT search results were re-scored and re-ranked
by a stand-alone version of the Percolator downloaded from the website
http://www.sanger.ac.uk/resources/software/mascotpercolator. The “rank delta N” value
was set at default = “1”, which means all peptide hit ranks that have a delta score of < 1
to the top hit match were processed. The false discovery rate (FDR) was set at 1%. Table
4.1 shows that Percolator not only increased the total peptide hits by 15%, but also
significantly decreased the FDR to 0.64% from the original 12.49%.
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Collectively, Percolator provided a standard post-MASCOT approach for the
significant improvement in increasing authentic phosphopeptide identification, and
reducing false positives resulting in a decreased FDR.

Statistical Analysis of the Quantitation and Identification of Light and Heavy
Thiocholine-Modified Phosphopeptides.
In our previous study, we employed BEMA with light and heavy thiocholine using
the tryptic phosphopeptide FQpSEEQQQTEDELQDK from β-casein to show that five
independent replicates at a theoretical ratio of 1:1 (light:heavy) produced an experimental
average of 0.96 ± 0.02; three independent replicates at theoretical ratios of 1:2, 1:3, 1:4,
4:1, 3:1, 2:1 together with five independent replicates at a theoretical ratio of 1:1
(light:heavy) yielded an experimental correlation coefficient of R2 = 0.99 (as described in
Chapter 2). These results show that the BEMA strategy with light and heavy thiocholine
is a reliable, reproducible and precise approach towards quantitative phosphoproteomics.
However, when dealing with complex tissue based systems, such as subject of the current
study, large deviations in the comparative quantitation analysis can be introduced through
multi-step sample preparation, run-to-run fluctuations in instrumentation parameters, or
simply by the intrinsic differences between individual biological replicates. Although
useful information could still be obtained by a limited number of replicates [21], relative
changes in phosphorylation were exclusively evaluated for all phosphopeptides identified
in three or more independent replicate samples (six samples overall) using relative peak
intensity ratios of the molecular ions of light and heavy thiocholine-modified peptides at
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the time of their co-elution. The relative ratio was calculated by dividing the light peak
intensity by the heavy peak intensity. Dixon's Q [34] test was used to eliminate the
outlier(s) with 95% confidence prior to the calculations of sample average and standard
deviation. A representative “M + 4” doublet pattern of the quadruply charged molecular
ions of light and heavy thiocholine-modified YHGHS*MSDPGVSYR at m/z 424.195 and
425.200, respectively is evident in Figure 4.5. The greater peak intensity of the heavy
thiocholine-modified YHGHS*MSDPGVSYR indicates that the phosphorylation level
was increased for this peptide following the induction of cardiac ischemia.
Peptide hits with a Percolator-processed posterior error probability (PEP) value <
0.05 (score > 13) indicating a confidence level of 95%, were considered automatic
positive identifications. Non-mitochondrial peptides with a score < 13 were considered
false positives. Peptides originating from mitochondrial proteins with a PEP > 0.05 but <
0.2 (7 < score < 13), indicating a confidence level between 80% and 95%) were verified
manually. Four mitochondrial peptides with a score between 7 and 13 were verified as
positive identifications. The mass spectra of these peptides are shown in Figure 4.6.
Phosphopeptides identified were categorized into six groups according to the number of
hits from the six individual biological replicates. Table 4.2-A contains thiocholinemodified peptides identified in all six individual biological replicates. There are 21
unique peptides identified containing 36 phosphorylation sites, 16 of which were not
reported in the literature. Ten out of the 21 peptides yielded a signature neutral loss in
MS3 which are highlighted in bold. The ratios in italic font indicate that the ratios are
calculated using heavy peak intensity over light peak intensity. Table 4.2-B contains
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thiocholine-modified peptides identified in five out of six individual biological replicates.
There are eight unique peptides identified containing 13 phosphorylation sites, five of
which were not reported before. Four out of the eight peptides yielded a signature neutral
loss in MS3. Table 4.2-C contains thiocholine-modified peptides identified in four out of
six individual biological replicates. There are nine unique peptides identified containing
17 phosphorylation sites, 15 of which were not reported before. Five out of the nine
peptides yielded a signature neutral loss in MS3. Table 4.2-D contains thiocholinemodified peptides identified in three out six of individual biological replicates. There are
eight unique peptides identified containing 16 phosphorylation sites, 14 of which were
not reported before. One out of the eight peptides yielded a signature neutral loss in MS3.
Table 4.2-E shows the thiocholine-modified peptides identified in two out of six
individual biological replicates. There are 11 unique peptides identified containing 20
phosphorylation sites, all of which were not reported before. Four out of the 11 peptides
yielded a signature neutral loss in MS3. Table 4.2-F shows thiocholine-modified peptides
identified in one out of six individual biological replicates. There are 84 unique peptides
identified containing 126 phosphorylation sites, 119 of which are novel. Three out of the
84 peptides yielded a signature neutral loss in MS3. No evaluation of quantitation was
assessed for peptides in the 1-hit and 2-hit groups out of six. Overall, 141
phosphopeptides were identified from 133 unique proteins with 228 phosphorylated sites
from six independent biological replicates, with 189 novel sites. Twenty-seven out 141
thiocholine-modified peptides yielded a signature neutral loss in MS3, with 24 out 57 if 1hit peptides are not included. Mitochondrial proteins were determined using the protein
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database UniProt [35-36] and the LOCATE database [37-38]. Proteins identified with
either the UniProt or LOCATE databases as mitochondrial proteins were considered to be
mitochondrial in origin. There are 36 phosphopeptides identified from 35 mitochondrial
proteins with 50 phosphorylated sites, of which 37 were not reported before. As shown in
Table 4.3, relative changes in phosphorylation were evaluated for mitochondrial
phosphopeptides identified in three or more independent replicate samples
To validate the above strategy, the well-characterized phosphorylation of cardiac
phospholamban at serine 16 induced during global cardiac ischemia in mouse hearts was
used as a test case for the methodology developed in this study. As previously reported,
phosphorylation at serine 16 of cardiac phospholamban was increased by 20-40 fold upon
20-min of ischemia in Langendorff-perfused rat hearts [17]. In our study, we identified
the light and heavy thiocholine-modified peptide RAS*TIEMPQQAR with a light over
heavy ratio of 0.05 ± 0.00 calculated from six replicates indicating an approximately 20fold increase in phosphorylation of the peptide, which is consistent the previous results
obtained using a traditional
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P-radiolabeling method from a similar system thereby

validating the quantitative approach employed in the current study.
Among all the mitochondrial peptides indentified, the peptide IVS*AQSLAEDDVE
showed the most significant and consistent change throughout all six samples. The heavy
thiocholine-modified peptide IVS*AQSLAEDDVE was identified, with extremely high
confidence and high mass accuracy (Table 4.3), in each and every sample. The absence of
the ion peak corresponding to the light thiocholine-modified IVS*AQSLAEDDVE
indicates that the net phosphorylation level was increased dramatically during the
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induced cardiac ischemia. The peptide IVS*AQSLAEDDVE (133-145) is a tryptic
peptide from the protein called mitochondrial import receptor subunit TOM20 located in
the outer membranes of mitochondria, which is an important receptor protein for
precursors of mitochondrial proteins that are synthesized in cytoplasm [51]. The
phosphorylation site of serine residue 135 is located within a domain that was
characterized in previous study [52] as a critical region responsible for the recognition of
protein possessing internal signaling sequence, rendering the phosphorylation of serine
135 a potential mechanism for the adaptive reactions of mitochondria during oxygen
deficiency.
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4.5 Conclusion

We demonstrated that β-elimination of phosphate and subsequent Michael addition
(BEMA) with light and heavy thiocholine together with TiO2 phosphopeptide enrichment
and the Percolator machine learning algorithm based MASCOT re-scoring program
provides a highly effective strategy for in vivo quantitative phosphoproteomics of tissuebased systems. The application of this strategy for the quantitative analysis of alterations
in the murine myocardial mitochondrial phosphoproteome subjected to global cardiac
ischemia resulted in the identification of 141 phosphopeptides from 133 unique proteins
with 228 phosphorylated sites, 189 of which were not reported before. Among all the
peptides identified, 36 were phosphopeptides from 35 mitochondrial proteins containing
50 phosphosites, 37 of which were not reported before. The strategy was validated by the
well-characterized phosphorylation of phospholamban at serine 16 during induced global
cardiac ischemia in mouse myocardium.
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4.7 Table Legends

Table 4.1
Improvement of peptide identification in MASCOT search results using Percolator.
A local MASCOT server with an up-to-date IPI mouse database was used to conduct all
searches as described in Materials and Methods. Database searches were conducted using
an automatic decoy database provided by the local MASCOT server. All MASCOT
search results were re-scored and re-ranked by a stand-alone version of the MASCOT
Percolator as described in Materials and Methods. The false discovery rate (FDR) was set
at 1%. All peptide hits with ion score greater than the “identification score” or the
“homology score” in the direct output results generated by MASCOT were counted. For
the Percolator processed results, all peptide hits with a posterior error probability (PEP)
value < 0.05 (score > 13) were counted. The “decoy hits” were those product-ion spectra
that matched peptide sequences in the decoy database. The False Identification Rate
(FDR%) was calculated by dividing the overall hits using the decoy hits. The Percolator
program not only increased the total hit number in each of the six samples, but also
significantly lowered the FDR%. Percolator increased the total number of peptide hits by
roughly 15% and lowered the overall FDR% from 12.29% to 0.64%.

Table 4.2
Identification of phosphorylation sites in proteins from mitochondria isolated from
control and ischemic mouse hearts using BEMA with light and heavy thiocholine.
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Tryptic peptides from proteins associated with mitochondria isolated from control and
ischemic mouse hearts were TiO2-enriched, and modified by light and heavy thiocholine,
respectively. The resultant light and heavy thiocholine samples were mixed, desalted,
separated using reverse-phase nanobore HPLC, and analyzed with an LTQ-Orbitrap
system as described in Materials and Methods. Mass spectrometry data were searched
utilizing MASCOT with the designated thiocholine modification as well as common
amino acid modifications as described in the Materials and Methods. Peptides were
identified using Percolator-processed MASCOT results as described in the Materials and
Methods. Relative change in phosphorylation due to ischemia was evaluated for all
phosphopeptides identified in three or more independent replicates as described in the
Materials and Methods. The ratios in italic font indicate that they were calculated using
heavy peak intensity over light peak intensity. “*” denotes phosphorylation sites; “(*)”
denotes that more than one phosphorylation site was identified in the same peptide and
that they were not concurrent. The superscripts “ace”, “ac”, “d”, and “o” denote the
following modifications: acetylation (N-terminus), acetylation (K), deamidation (NQ)
and oxidation (M), respectively. All cysteine residues were carbamidomethylated.
Peptides which yielded a signature neutral loss pattern in MS3 are highlighted in bold.

A. Thiocholine-modified peptides identified in all six individual biological replicates.
There are 21 unique peptides identified containing 36 phosphorylation sites, 16 of which
were not reported before. Ten out of the 21 peptides yielded a signature neutral loss in
MS3.

158

B. Thiocholine-modified peptides identified in five out of six individual biological
replicates. There are eight unique peptides identified containing 13 phosphorylation sites,
five of which were not reported before. Four out of the eight peptides yielded a signature
neutral loss in MS3.
C. Thiocholine-modified peptides identified in four out of six individual biological
replicates. There are nine unique peptides identified containing 17 phosphorylation sites,
15 of which were not reported before. Five out of the nine peptides yielded a signature
neutral loss in MS3.
D. Thiocholine-modified peptides identified in three out six of individual biological
replicates. There are eight unique peptides identified containing 16 phosphorylation sites,
14 of which were not reported before. One out of the eight peptides yielded a signature
neutral loss in MS3.
E. Thiocholine-modified peptides identified in two out of six individual biological
replicates. There are 11 unique peptides identified containing 20 phosphorylation sites, all
of which were not reported before. Four out of the 11 peptides yielded a signature neutral
loss in MS3.
F. Thiocholine-modified peptides identified in one out of six individual biological
replicates. There are 84 unique peptides identified with 126 phosphorylation sites, 119 of
which were not reported before. Three out of the 84 peptides yielded a signature neutral
loss in MS3.
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Table 4.3
Identification of phosphorylation sites from mitochondrial proteins isolated from
control and ischemic mouse hearts using BEMA with light and heavy thiocholine.
Tryptic peptides from proteins associated with mitochondria isolated from control and
ischemic mouse hearts were TiO2-enriched, and modified by light and heavy thiocholine,
respectively. The modified peptides were mixed, desalted, and separated using reversephase nanobore HPLC, before analysis with an LTQ-Orbitrap system as described in
Materials and Methods. Mass spectrometry data were searched utilizing MASCOT with
the designated thiocholine modification as well as common amino acid modifications as
described in the Materials and Methods. Peptides were identified using Percolatorprocessed MASCOT results as described in the Materials and Methods. Mitochondrial
proteins were identified using both UniProt and LOCATE. No attempts have been made
to reassign the subcellular locations predicted by UniProt and LOCATE. Relative changes
in phosphorylation were evaluated only for mitochondrial phosphopeptides identified in
three or more independent replicates as described in the Materials and Methods. The
ratios in italic font indicate that they were calculated using heavy peak intensity over light
peak intensity. “*” denotes phosphorylation sites; “(*)” denotes that more than one
phosphorylation site was identified in the same peptide that were not concurrent with
other phosphorylation sites within the same peptide. The superscripts “ace”, “ac”, “d”,
and “o” denote the following modifications: acetylation (N-terminus), acetylation (K),
deamidation (NQ) and oxidation (M), respectively. All cysteine residues were
carbamidomethylated. Peptides which yielded a signature neutral loss pattern in MS3 are
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highlighted in bold. Collectively, there were 36 unique peptides identified with 50
phosphorylation sites, 37 (indicated with underscore) of which were not reported before.
Eight out of the 36 peptides yielded a signature neutral loss in MS3.
“a”: Proteins that are known to be other subcellular locations but are associated with
mitochondria and are listed as mitochondrial proteins in UniProt and LOCATE.
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Table 4.1

1

MASCOT
Hits
1509

MASCOT Decoy
Hits
194

FDR%

Percolator Hits

12.86

1782

Percolator Decoy
Hits
9

2

1815

3

2156

210

11.57

2165

14

0.65

274

12.71

2429

17

0.70

4

1867

241

12.91

2177

15

0.69

5

2013

259

12.87

2288

14

0.61

6

2177

263

12.08

2464

16

0.65

Total

11537

1441

12.49

13305

85

0.64

Sample

162

FDR%
0.51

Table 4.2
A.
Protein

Peptide Sequence

Δm
(ppm)

Percolator
Score

Ratio

Isoform 1 of
Tropomyosin alpha-1
chain

AISEELDHALNDMT(*)S*I

1.2

152.2

1.08±0.36

Alpha-crystallin B
chain

APS*WIDTGLSEMR

1.4

94.6

0.00±0.00

Vinculin

DPNAS*PGDAGEQAIR

0.1

152.7

0.67±0.25

DWEDDS*DEDMSNFDR

-0.1

114.5

0.53±0.40

EADEEDS*DEETS(*)YPER

1.0

127.2

1.15±0.23

EFDELSPS*AQR

1.7

16.4

1.22±0.21

GDQVS*QdNGLPAEQGSPR

2.2

106.4

0.91±0.11

GPQFGS*EVELR

1.7

44.3

2.13±0.79

IVS*AQSLAEDDVE

-0.6

152.7

0.00±0.00

LPSGS*GPAS(*)PTTGSAVDIR

2.0

88.3

0.52±0.19

QAS*EQNWANYSAEQNR

1.3

152.9

1.48±0.32

QLS*SGVSEIR

1.9

29.0

0.04±0.08

RAS*T(*)IEMPQQAR

3.4

151.0

0.05±0.05

S(*)QS*FPDVEPQLPQAPTR

2.0

63.6

0.65±0.33

S(*)T(*)S*PAPADVAPAQEDLR

2.2

69.2

0.79±0.28

TAS(*)LT*S(*)AASIDGSR

1.0

152.4

0.34±0.28

TEDGGWEWS*DDEFDEESEEGR

-3.1

152.7

0.80±0.40

Prostaglandin E
synthase 3
Uncharacterized
protein C6orf203
homolog
Isoform SERCA2A
of
Sarcoplasmic/endopla
smic reticulum
calcium ATPase 2
Isoform 2 of Spectrin
beta chain, brain 1
Isoform Somatic of
Angiotensinconverting enzyme
Mitochondrial import
receptor subunit
TOM20 homolog
AHNAK
nucleoprotein isoform
1
Gap junction protein
Isoform A of Heat
shock protein beta-1
Cardiac
phospholamban
Tensin 1
Ras GTPaseactivating proteinbinding protein 1
Isoform 1 of Protein
NDRG2
Oxsr1
Serine/threonineprotein kinase OSR1
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Protein

Δm
(ppm)

Percolator
Score

Ratio

T(*)LS(*)PT*PS(*)AEGYQDVR

1.4

152.9

0.87±0.18

T(*)LS*QSS(*)ESGTLPSGPPGHTMEV
SC

0.6

152.7

0.39±0.29

YHGHS(*)MS*DPGVSYR

0.8

39.5

0.57±0.43

YTDQS*GEEEEDYESEEQLQHR

1.1

152.6

1.36±0.37

Peptide Sequence

Putative
uncharacterized
protein
Isoform 1 of Protein
NDRG2
Pyruvate
dehydrogenase E1
component subunit
alpha
Ubiquinone
biosynthesis protein
COQ9, mitochondrial

B.
Δm
(ppm)

Percolator
Score

Ratio

GPDEAIEDGEEGS*EDDAEWVVTK

1.2

152.9

0.61±0.27

GVS*VS(*)SGTGLPDMoT*GSVYNKac

3.2

21.7

0.00±0.00

ILGADT*S(*)VDLEETGR

0.0

56.2

1.49±0.52

MGQAGS*T(*)IS(*)NSHAQPFDFPDDSQNA
K

-0.5

128.6

1.00±0.08

S*ASADNLILPR

1.0

35.5

0.81±0.21

Protein
EH domaincontaining
protein 2
Ubiquitinassociated
protein 2
ATP synthase
subunit alpha,
mitochondrial
Gap junction
protein
Isoform 1 of
Cyclin-Y
Histone H1.4
Catenin alpha-1
Thioredoxinrelated
transmembrane
protein 1

Peptide Sequence

ace

1.2

45.6

1.02±0.25

TPEELDDS*DFETEDFDVR

S*ET(*)APAAPAAPAPAEK

-1.7

47.1

0.83±0.13

VEEEQEADEEDVS*EEEAEDR

0.8

152.9

1.28±0.43
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C.
Δm
(ppm)

Percolator
Score

Ratio

DPALDTNdGSLATPS*PS(*)PEAR

-0.3

48.5

0.37±0.17

ace

EANdNdGSSPAGSLADAMS*QK

0.8

31.3

1.72±0.61

ace

EQdSRQDEPPSNSQdEVNdS*DDR

0.1

33.6

0.00±0.00

LGYILTCPS(*)NLGT*GLR

0.5

24.8

1.32±0.32

MGQAGS(*)T*IS*NS(*)HAQPFDFPDDSQNA
K

1.6

27.4

0.00±0.00

NLS*IYDGPEQR

1.1

20.0

0.88±0.51

RIS(*)QT*SQVSIDAAHGYSPR

3.0

47.3

1.06±0.70

RS*SQPSPT(*)T(*)VPASDSPPAK

1.6

26.2

0.14±0.28

-2.8

50.0

0.00±0.00

Protein
Isoform 3 of
LIM domainbinding protein
3
Signal
transducer and
activator of
transcription
5B
Isoform 1 of
Zinc finger
protein 106
Creatine
kinase S-type,
mitochondrial
Gap junction
protein
Electron
transfer
flavoproteinubiquinone
oxidoreductase
, mitochondrial
Ryanodine
receptor 2,
cardiac
Isoform 1 of
MAP7
domaincontaining
protein 1
LIM
homeobox
transcription
factor 1-beta

Peptide Sequence

S*EDEDGDMoKaPAKaGQGSQSKaGS(*)GDDGK
ac
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D.
Δm
(ppm)

Percolator
Score

Ratio

0.4

16.73

1.62±0.70

1.2

65.52

0.00±0.00

-0.1

17.19

0.00±0.00

-1.7

61.24

0.00±0.00

GPSGTDT*VS(*)GQSNSGNdNGNNGKDR

-3.1

31.50

0.00±0.00

NDS*IVTPSPPQAR

0.3

19.41

0.32±0.30

NST(*)LS*EEDYIER

4.2

19.87

1.05±0.12

TGTAEMS(*)S*ILEER

1.8

51.80

0.73±0.78

Protein
Troponin I,
cardiac muscle
Isoform 1 of
Protein
FAM54B
Putative
uncharacterize
d protein
Discs, large
homolog 3
Isoform 1 of
Trinucleotide
repeatcontaining
gene 6B
protein
Isoform 1 of
Mitochondrial
fission factor
Similar to E1B
19K/Bcl-2binding protein
homolog
ATP synthase
subunit alpha,
mitochondrial

Peptide Sequence
ace

ADESS*DAAGEPQPAPAPVR

AS(*)S*FADMMGILK
ace

DQPGHES(*)NT(*)SGNGSNMoWPNFPS*QdD

K
ace

ENMoAQENdSIQdEQGVTSNT*SDSES(*)SS(*)

K
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E.
Δm
(ppm)

Percolator
Score

0.9

15.6

DLS*SS(*)PPGPYGQEMYVFR

-0.8

114.1

ENdLQNGNLNDPS*SIESS(*)NGQdWPKac

0.2

14.0

ENdNVS*QdPASS(*)SSSSSSSNdNdGSSSPTKTK

3.6

16.7

IEGGS(*)SNVFS*MFEQTQIQEFK

0.6

60.0

IS(*)QTS*QVSIDAAHGYSPR

1.0

67.0

LYVVDS*INDLNK

0.5

24.2

4.7

19.1

T(*)PS*LLEQEVKPSTELEYLGPDEND

0.3

34.5

VAEPEES*EAEEPAAEGR

0.0

20.9

WLPAGTGPQAFSR

3.2

27.4

Protein
Metabotropic glutamate
receptor 8
5'-AMP-activated protein
kinase subunit beta-2
Similar to mKIAA1614
protein isoform 1
Transcription factor Sp4
Myosin regulatory light
chain 2,
ventricular/cardiac muscle
isoform
Ryanodine receptor 2,
cardiac
Isoform 1 of Coiled-coil
domain-containing
transmembrane protein
C7orf53 homolog
CXXC-type zinc finger
protein 5
Solute carrier family 2
(facilitated glucose
transporter), member 4
Putative uncharacterized
protein
Vasodilator-stimulated
phosphoprotein

Peptide Sequence
ace

ace

K

AVNdFNGS*AGTPVTFNENdGDAPGR

MoS*SLGGGSQDAGGSSSSSNdTNdSSSGS*GQd

ac
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F.
Peptide Sequence

Δm
(ppm)

Percolator
Score

AGGDIRVLVPYNSTGVLGGSTTLHCSLT*S*NdENdVT*
ITQdITWMKKac

-3.3

80.4

YS*DRKK

2.2

56.0

DRSDSDDQMLVANdGSPS*SNLSSSVR

0.1

50.0

4.0

47.9

-4.1

43.0

1.0

40.0

NVST*GVVELK

-0.5

38.0

T*IVVGNdVSK

2.1

31.7

ace

MDPNdCS*CAAGDSCTCAGSCKac

0.0

31.5

ace

VAEGSS*EGATANIEAYRPSPK

1.4

31.3

EPALNEANdLS*NLK

5.0

31.0

TVAENDAAQdPGSMSSSSSS*SSLDHK

0.0

30.7

KacMSGGSTMoS*S*GGGNTNNdSNSKacK

1.8

29.7

ace

AVSEQdDT*KQAEAVT*SPR

-0.7

26.6

QSNS*YDMFMoRGEEILSGAQdR

4.5

26.5

S*IS*FLGCALQMVIS*LGLGS*TECVLLAVMAYDRYA
AICNPLR

0.1

26.3

GEESNESAEASS*NdWEK

3.5

26.1

NPPPQDYES*DDESYEVLDLTEYAR

2.8

25.9

Protein
Poliovirus receptor
Coiled-coil domaincontaining protein
93
Putative
uncharacterized
protein
Rap1 GTPaseactivating protein
Isoform 2 of Protein
MRVI1
Dnajc5 protein
Synaptotagmin-12
Isoform 2 of
YEATS domaincontaining protein 2
Metallothionein
Isoform 1 of PDZ
domain-containing
RING finger protein
3
Proteasome activator
complex subunit 1
Isoform 1 of CAPGly domaincontaining linker
protein 4
Isoform 1 of LIM
domain-binding
protein 1
Tyrosine 3monooxygenase
Aspartyl-tRNA
synthetase,
cytoplasmic
Olfactory receptor
Olfr270
Isoform 2 of
SWI/SNF-related
matrix-associated
actin-dependent
regulator of
chromatin subfamily
A containing
DEAD/H box 1
FUN14 domain-

SENS*STQdSSPEMoPTTKNR
d

d

o

ac

FNALN LPGQ APS*S*SPM PSLPALSESSNGK SSISVS
*PALPALLENGK
SLS*TSGESLYHVLGLDK
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Δm
(ppm)

Percolator
Score

HLGGSGSVVPGS*PSLDR

2.0

25.4

ace

3.8

22.5

MQGQEQdT*T*MoAVVPGGAPPSENSVMoK

0.1

22.3

EES*EES*EDDMGFGLFD

-0.3

21.4

TDGKEEEEQPSTS*ATQSSPAPGQSK

2.8

21.2

YSGDSDSSASSAQS*GPMoGARSDDSATGSR

2.8

20.9

RSDSAPPSPVS*ATVPEEEPPAPR

2.4

20.6

EVQNdDLMLQdS*NdGS*QYSPNEIRENSPSVS*PT*ANI
AAPFGLKPR

4.1

20.4

Protein

Peptide Sequence

containing protein 1
Tensin 1
Diphosphoinositol
polyphosphate
phosphohydrolase 3alpha
Membrane-spanning
4-domains,
subfamily A,
member 4C
60S acidic ribosomal
protein P1
Ep300 protein
Isoform 1 of GAS2like protein 1
Junctophilin-2
Putative
uncharacterized
protein
Ring finger protein
112
Isoform 2 of CCR4NOT transcription
complex subunit 10
IgE-binding protein
[Protein ADPribosylarginine]
hydrolase-like
protein 1
Secreted seminalvesicle Ly-6 protein
1
Isoform 1 of Xin
actin-binding repeatcontaining protein 2
Similar to
LOC635138 protein
Cell surface
glycoprotein CD200
receptor 2
ADAM DEC1
Isoform 1 of
Pleckstrin homology
domain-containing
family H member 2
Glycerol-3phosphate
acyltransferase 1,
mitochondrial

LGGSPTNdGNS*AAPS*PPES*EP

ace

SFMoGNSSNdSWS*HAS*FPKac

1.1

20.0

ace

QENdGSKSSSQLGGNTESSES*SETCSKac

-3.6

19.7

TDNGPAYT*SQdK

1.4

19.7

ENS*VLGSIQEELQK

2.2

19.6

LNS*SGICETAETSCEAT*NdNdR

1.4

19.5

ace

5.0

18.9

2.9

18.8

NIT*WAS*TPDHIPDLQIS*AVALQHEGNYLCEITT*P
EGNFHK

4.8

18.6

NdNdVALVALMS*HELGHALGMoK

-2.4

18.5

S*QSGVK

4.4

18.4

SDEEDEDS*DFGEEQR

0.2

18.2

QEGIQNSSDASQSKLACET*SQdSHKa

MoAASAAAATAAGIAMoATSVQSSTTVEQLS*S*S*VA
EVIDQdHSVLSAQLK
ace
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Protein

Peptide Sequence

Δm
(ppm)

Percolator
Score

COMM domaincontaining protein 4
Ankyrin repeat and
SOCS box protein 7

VDYT*LS*SSLLHSVEEPMoVHLQLQdVVPAPGTQAQP
VSMoSLS*ADKac

0.9

18.1

-4.1

18.1

0.0

18.1

0.6

17.4

YQDEVFGGFVTEPQEES*EEEVEEPEER

-0.8

17.2

VLQdHILNPAFLYSFEKGEGEQLLGPPNPEGDNdPESIT*
S*VFITKac

-0.9

17.0

NdEGVSSVLLGS*S*T*PEQdLIENLGAIQdVLPKacMoTSH
VVNdEIDNdILR

0.3

16.6

MASSMoVAQQdTVPTVSGSLTPQdPSPQdLPTPKTLGG
PVQS*SLVSELKQK

-2.2

16.3

GDTTS*S*AET*QdPASSSSAEGPAAK

-2.7

16.3

FS*VNdAVYS*K

-0.1

16.1

ace

HS*NHSTENdSPIER

-0.4

16.1

ace

QEPSSQGSQS*ALQdTHELGGETLK

-1.7

16.1

DFLAGGIAAAVS*K

0.8

16.0

ALGSVLNdAS*TVAAAMCMVVTR

-2.0

15.7

ace

GMAADVGMGGFS*QdGPGNdPGNdMMF

-3.3

15.5

ace

S*GLSDLAESLTNDTET*NS*

2.1

15.3

DDAT*DKacDLSDLVS*EMoEMMK

3.8

15.2

ace

-1.6

15.2

HTEESAQMVET*PR

1.1

15.2

ace

0.8

15.1

ace
ace

22 kDa protein
Vomeronasal 2,
receptor 95
Ras GTPaseactivating proteinbinding protein 1
Transformation/trans
cription domainassociated protein
Voltage-gated
potassium channel
subunit beta-1

MLYNYGADT*NTR
d

ac

d

AEKLS*EQ PQS*AAS*GSSAAGPSQSK QGSLLN LL
AEPSKPVGHASIFK
ace

CTPCAVNEIS*NETDVDQdCVK

ace

Protocadherin-21
Hypothetical protein
isoform 2
Hydrocephalus
inducing protein
Isoform 1 of
Voltage-dependent
L-type calcium
channel subunit
beta-4
Isoform 1 of
Transmembrane
protein 154
ADP/ATP
translocase 1
60 kDa SS-A/Ro
ribonucleoprotein
B-cell
CLL/lymphoma 9
protein
THO complex
subunit 1
Isoform 1 of
Fibroblast growth
factor receptor 3
Biorientation of
chromosomes in cell
division 1-like
Expressed sequence
AA415398
Isoform 1 of
Perilipin-4

NdEECDGLMAS*TASCDVSNdKDSLAGSK

DTVCAGVTS*AMNMAK
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Δm
(ppm)

Percolator
Score

-1.6

15.1

LIDGIVLTKFDTIDDKacVGAAISMoT*YITSKacPIVFVGT
GQTYCDLR

-3.3

15.0

TTS*LQdNGT*FHLK

0.4

14.9

CRAS*AWASISMAS*TVHGCMR

-1.3

14.8

ace

-0.1

14.7

QdSCTFTGSSSQdALVAPGNdT*PTTH

-0.8

14.6

ace

ETTSTT*QPPASNdPQdWGAEPHR

2.0

14.5

ace

KacS*DSGVMLPTLR

-4.0

14.5

ace

MSLQdEPSQGGPASSSNS*LDMNGR

2.2

14.4

TYTSTSNNdSISGSLNRLEDT*AAR

4.3

14.4

ace

TDLGISNSFSHSS*GELLIK

1.2

14.3

ace

QdNdENRPCDT*KPNdDNK

-1.7

14.1

CLKDNS*AIK

3.0

14.0

KacNdSTSST*S*NSSAGNTTNdSAGSK

4.2

13.8

ace

NdISNMoS*NMNdSSR

1.1

13.8

ace

LLGVLATSS*SSLGFESDPETSCR

1.8

13.5

S*GFS*K NGVTVSLSGATTM SVNISTIGTIIT*FDGNI
FQIWLPYR

-0.2

13.5

SGS*NDDSDIDIQEDDES*DSELEDR

0.7

13.4

ace

4.9

13.3

DDGDN PET*IMSSGN VNSSS

-3.3

13.3

ace

-0.2

13.3

Protein
Prickle-like 2
isoform a
Signal recognition
particle receptor
subunit alpha
Putative
uncharacterized
protein
Putative
uncharacterized
protein
Nucleolar protein 12
Coiled-coil domaincontaining protein
87
Protocadherin 15
isoform CD1-4
Isoform 1 of DENN
domain-containing
protein 5B
Isoform 1 of
Calcium/calmodulin
-dependent protein
kinase kinase 2
Protein AF-10
Zinc finger, FYVE
domain containing 9
Isoform 2 of
Nipped-B-like
protein
Isoform 1 of Integrin
beta-2-like protein
Isoform 1 of LIM
domain-binding
protein 2
Glutamate [NMDA]
receptor subunit
epsilon-1
Similar to
hCG2038359
Mucin 5, subtype B,
tracheobronchial
Clusterin-associated
protein 1
Fibrillin-1
Sphingosine-1phosphate receptor 1
Mitochondrial
import receptor

Peptide Sequence
ace

MoEQNQdS*QdSPLQdLLSQdCNIR

QEEGSTS*QEGGGTPR

ace

a

o

CDEGYES*GFMoMoMoKacNdCMDIDECQdR
d

d

AAAVAAAGAGEPLS*PEELLPK
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Protein
subunit TOM22
homolog
Isoform 2 of Tumor
protein 63
Similar to
1700001E04Rik
protein isoform 5
Trifunctional
enzyme subunit
alpha, mitochondrial
Isoform 3 of A
kinase anchor
protein 1,
mitochondrial
Cytochrome b-c1
complex subunit 2,
mitochondrial
Branched chain keto
acid dehydrogenase
E1, alpha
polypeptide

Δm
(ppm)

Percolator
Score

QdT*SMQdSQdSSYGNdSSPPLNKacMNdSMoNdKac

0.3

13.2

TMLDMoNdEMTQSIIGS*MQYSK

3.6

13.1

AGLEQGSDAGYLAES*QK

2.1

9.5

RLS*EEACPGVLSVAPTVTQPPGR

1.6

9.2

AVAQGNLSS*ADVQAAK

2.4

9.1

IGHHSTSDDS*SAYR

0.9

8.4

Peptide Sequence
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Table 4.3

Protein
Alpha-crystallin B
chain
Uncharacterized
protein C6orf203
homolog
Mitochondrial
import receptor
subunit TOM20
homolog
Isoform A of Heat
shock protein beta-1
Cardiac
phospholambana
Pyruvate
dehydrogenase E1
component subunit
alpha, somatic
form, mitochondrial
Ubiquinone
biosynthesis protein
COQ9,
mitochondrial
EH domaincontaining protein 2
ATP synthase
subunit alpha,
mitochondrial
Creatine kinase Stype, mitochondrial
Electron transfer
flavoproteinubiquinone
oxidoreductase,
mitochondrial
Isoform 1 of
Mitochondrial
fission factor
ATP synthase
subunit alpha,
mitochondrial
Isoform 1 of CAPGly domaincontaining linker
protein 4
FUN14 domaincontaining protein 1
60S acidic

Hits

Ratio

Source

Percolator
Score

Δm
(ppm)

APS*WIDTGLSEMR

6

0.00±0.00

Both

94.6

1.4

EADEEDS*DEETS(*)YPER

6

1.15±0.23

Both

127.2

1.0

IVS*AQSLAEDDVE

6

0.00±0.00

Both

152.7

-0.6

QLS*SGVSEIR

6

0.04±0.08

LOCATE

29.0

1.9

RAS*T(*)IEMPQQAR

6

0.05±0.05

Both

151.0

3.4

YHGHS(*)MS*DPGVSYR

6

0.57±0.43

Both

39.5

0.8

YTDQS*GEEEEDYESEEQLQHR

6

1.36±0.37

Both

152.6

1.1

GPDEAIEDGEEGS*EDDAEWV
VTK

5

0.61±0.27

LOCATE

152.9

1.2

ILGADT*S(*)VDLEETGR

5

1.49±0.52

Both

56.2

0.0

LGYILTCPS(*)NLGT*GLR

4

1.32±0.32

Both

24.8

0.5

NLS*IYDGPEQR

4

0.88±0.51

Both

20.0

1.1

NDS*IVTPSPPQAR

3

0.32±0.30

UniProt

19.4

0.3

TGTAEMS(*)S*ILEER

3

0.73±0.78

Both

51.8

1.8

TVAENDAAQdPGSMSSSSSS*SS
LDHK

1

--

LOCATE

30.7

0.0

1

--

LOCATE

25.9

2.8

1

--

LOCATE

21.4

-0.3

Peptide Sequence

NPPPQDYES*DDESYEVLDLTE
YAR
EES*EES*EDDMGFGLFD
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Peptide Sequence

Hits

Ratio

Source

Percolator
Score

Δm
(ppm)

SFMoGNSSNdSWS*HAS*FPKac

1

--

LOCATE

20.0

1.1

TDNGPAYT*SQ K

1

--

LOCATE

19.7

1.4

ENS*VLGSIQEELQK

1

--

LOCATE

19.6

2.2

SDEEDEDS*DFGEEQR

1

--

Both

18.2

0.2

1

--

LOCATE

18.1

0.9

1

--

LOCATE

16.6

0.3

1

--

LOCATE

16.3

-2.2

FS*VNdAVYS*K

1

--

LOCATE

16.1

-0.1

DFLAGGIAAAVS*K

1

--

Both

16.0

0.8

1

--

LOCATE

15.1

0.8

LIDGIVLTKFDTIDDK VGAAIS
MoT*YITSKacPIVFVGTGQTYCD
LR

1

--

LOCATE

15.0

-3.3

TTS*LQdNGT*FHLK

1

--

LOCATE

14.9

0.4

1

--

LOCATE

14.5

2.0

1

--

LOCATE

14.5

-4.0

1

--

LOCATE

13.4

0.7

1

--

Both

13.3

-0.2

AGLEQGSDAGYLAES*QK

1

--

Both

9.5

2.1

RLS*EEACPGVLSVAPTVTQPPG

1

--

Both

9.2

1.6

Protein
ribosomal protein
P1
Ring finger protein
112
IgE-binding protein
[Protein ADPribosylarginine]
hydrolase-like
protein 1
Glycerol-3phosphate
acyltransferase 1,
mitochondrial
COMM domaincontaining protein 4
Voltage-gated
potassium channel
subunit beta-1
Protocadherin-21
Hydrocephalus
inducing protein
ADP/ATP
translocase 1
Isoform 1 of
Perilipin-4
Signal recognition
particle receptor
subunit alpha
Putative
uncharacterized
protein
Protocadherin 15
isoform CD1-4
Isoform 1 of DENN
domain-containing
protein 5B
Clusterin-associated
protein 1
Mitochondrial
import receptor
subunit TOM22
homolog
Trifunctional
enzyme subunit
alpha,
mitochondrial
Isoform 3 of A

ace

d

VDYT*LS*SSLLHSVEEPMoVHL
QLQdVVPAPGTQAQPVSMoSLS*
ADKac
NdEGVSSVLLGS*S*T*PEQdLIEN
LGAIQdVLPKacMoTSHVVNdEIDN
d
ILR
ace
MASSMoVAQQdTVPTVSGSLT
PQdPSPQdLPTPKTLGGPVQS*SL
VSELKQK

ace

DTVCAGVTS*AMNMAK
ac

ace

ETTSTT*QPPASNdPQdWGAEP
HR
ace

KacS*DSGVMLPTLR

SGS*NDDSDIDIQEDDES*DSEL
EDR
ace

AAAVAAAGAGEPLS*PEELLP

K
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Hits

Ratio

Source

Percolator
Score

Δm
(ppm)

AVAQGNLSS*ADVQAAK

1

--

Both

9.1

2.4

IGHHSTSDDS*SAYR

1

--

Both

8.4

0.9

Protein
kinase anchor
protein 1,
mitochondrial
Cytochrome b-c1
complex subunit 2,
mitochondrial
Branched chain
keto acid
dehydrogenase E1,
alpha polypeptide

Peptide Sequence
R
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4.8 Figure Legends

Figure

4.1

Workflow

of

comparative

quantitative

phosphoproteomics

of

mitochondria from control mouse hearts and hearts rendered ischemic.
Mitochondria were isolated from both normally perfused and global ischemic mouse
hearts. Next mitochondrial proteins were extracted by methanol/chloroform precipitation.
Precipitated proteins were solubilized in Rapigest detergent and the protein concentration
was determined using a BCA kit. From each sample 1 mg of protein was trypsinized in
the presence of Rapigest. The resultant tryptic peptides were passed through a titanium
dioxide micro column for the selective enrichment of phosphopeptides. The
phosphopeptides were then desalted and modified with light thiocholine (control) and
heavy thiocholine (ischemic). Control and ischemic samples were mixed together,
desalted and analyzed using LC-MS/MS. The mass spectrometry data were searched
using MASCOT and re-scored by Percolator program to yield the identification of the
peptide. Quantitative information was obtained from the relative peak intensity of the
molecular ions of the phosphopeptides modified by light and heavy thiocholine
respectively. Proteins of mitochondrial origin were confirmed using both the UniProt and
LOCATE databases.

Figure 4.2 The total ion chromatography (TIC) (0-185 min) obtained from a
representative sample using LTQ-Orbitrap as described in Materials and Methods
(A). The extracted ion chromatography (XIC) (0-185 min) of the full-mass scans
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from the TIC (B).

Figure

4.3

Fragmentation

of

the

heavy

thiocholine-modified

peptide

YHGHS*MSDPGVSYR identified in the subunit α of pyruvate dehydrogenase E1
at both the MS2 and MS3 levels. All fragment ions resulting from heavy thiocholinemodified peptides are presented in capital letters (e.g., A, B and Y). All fragment
ions resulting from light thiocholine-modified peptides are presented in lower case
letters (e.g., a, b and y).
A. The product-ion spectrum of the quadruply charged molecular ion modified by heavy
thiocholine at m/z 425.200 (YHGHS*MSDPGVSYR) was obtained with an ESI-LTQOrbitrap instrument as described in the Materials and Methods. Shown in the spectrum
are the series of B ions, B8+2 at m/z 510.9, B10+2 at m/z 588.2, B11+2 at m/z 637.5, B12+3 at
m/z 454.6. Also shown in the spectrum is an example of the diagnostic triad consisting of
the B10+2 fragmentation ions resulting from peptide bond cleavage (m/z = 510.9) and
further neutral loss of

13

C,d3-trimethylamine (-63 Da, m/z = 556.8) or the

13

C,d3-

thiocholine thiolate (-123 Da, m/z = 526.7). “S*” indicates the thiocholine-modified site.
B. The expanded product-ion spectrum of the quadruply charged molecular ion modified
by heavy thiocholine at m/z 425.200 (YHGHS*MSDPGVSYR) ranging from m/z 380 to
m/z 640. As shown in the spectrum, the heavy thiocholine containing B ions are
accompanied by the corresponding light thiocholine containing b ions resulting from the
fragmentation of the light thiocholine-modified molecular ion at m/z 424.195
(YHGHS*MSDPGVSYR) that could not be excluded during the data-dependent
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dissociation, thereby generating a series of B/b ion doublets at the MS2 level with relative
ratios that further confirmed the comparative quantitation at the molecular level.
C. The MS3 spectrum of the B11+2 ion at m/z 637.5 resulting from the fragmentation of
the quadruply charged molecular ion modified by heavy thiocholine at m/z 425.200
(YHGHS*MSDPGVSYR) obtained with an ESI-LTQ-Orbitrap as described in
the Materials and Methods. The ion peak at m/z 606.1 corresponds to the doubly charged
fragment ion generated from the neutral loss of 13C,d3-trimethylamine (-63 Da) from the
parent ion B11+2.
D. The MS3 spectrum of the B10+2 ion at m/z 588.2 resulting from the fragmentation of
the quadruply charged molecular ion modified by heavy thiocholine at m/z 425.200
(YHGHS*MSDPGVSYR) obtained with an ESI-LTQ-Orbitrap as described in
the Materials and Methods. The ion peak at m/z 556.6 corresponds to the doubly charged
fragment ion generated from the neutral loss of 13C,d3-trimethylamine (-63 Da) from the
parent ion B10+2.
E. The MS3 spectrum of the B8+2 ion at m/z 510.9 resulting from the fragmentation of the
quadruply charged molecular ion modified by heavy thiocholine at m/z 425.200
(YHGHS*MSDPGVSYR) obtained with an ESI-LTQ-Orbitrap as described in
the Materials and Methods. The ion peak at m/z 479.5 corresponds to the doubly charged
fragment ion generated from the neutral loss of 13C,d3-trimethylamine (-63 Da) from the
parent ion B8+2.
F. The MS3 spectrum of the B12+3 ion at m/z 454.6 resulting from the fragmentation of the
quadruply charged molecular ion modified by heavy thiocholine at m/z 425.200
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(YHGHS*MSDPGVSYR) obtained with an ESI-LTQ-Orbitrap as described in
the Materials and Methods. The ion peak at m/z 433.6 corresponds to the triply charged
fragment ion generated from the neutral loss of 13C,d3-trimethylamine (-63 Da) from the
parent ion B12+3.

Figure 4.4 Workflow of MASCOT Percolator reproduced with permission from
Journal of Proteome Research, 2009, 8, 3176-3181 by M, Brosch, L. Yu, T. Hubbard,
and J. Choudhary.

Figure 4.5 Comparative quantitation of light and heavy thiocholine-modified
peptides.
Relative changes in phosphorylation were evaluated for all phosphopeptides identified in
three or more independent replicate samples as described in the Materials and Methods.
Evident in the spectrum is the “M + 4” doublet pattern of the quadruply charged
molecular ions of light and heavy thiocholine-modified YHGHS*MSDPGVSYR at m/z
424.195 and 425.200 respectively. The greater peak intensity of the heavy thiocholinemodified YHGHS*MSDPGVSYR indicates that the phosphorylation level was increased
for this peptide during induced cardiac ischemia. The relative ratio of the light and heavy
molecular ion “S*” indicates that the phosphoserine residue was either modified by light
or heavy thiocholine.
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Figure 4.6 Tandem mass spectra of manually verified mitochondrial peptides with a
score greater than 7 and less than 13. All fragment ions resulting from heavy
thiocholine-modified peptides are presented in capital letters (e.g., A, B and Y). All
fragment ions resulting from light thiocholine-modified peptides are presented in
lower case letters (e.g., a, b and y).

A.

The

product-ion

spectrum

of

the

triply

charged

molecular

ion

of

AGLEQGSDAGYLAES*QK originating from protein trifunctional enzyme subunit α,
modified by heavy thiocholine at m/z 610.307 was obtained with an ESI-LTQ-Orbitrap
instrument as described in the Materials and Methods. “S*” indicates the thiocholinemodified site.
B.

The

product-ion

spectrum

of

the

triply

charged

molecular

ion

of

AVAQGNLSS*ADVQAAK originating from protein cytochrome b-c1 complex subunit
2, modified by light thiocholine at m/z 544.292 was obtained with an ESI-LTQ-Orbitrap
instrument as described in the Materials and Methods. “S*” indicates the thiocholinemodified site.
C. The product-ion spectrum of the quadruply charged molecular ion of
IGHHSTSDDS*SAYR originating from protein branched chain keto acid dehydrogenase
E1-α polypeptide, modified by light thiocholine at m/z 409.191 was obtained with an
ESI-LTQ-Orbitrap instrument as described in the Materials and Methods. “S*” indicates
the thiocholine-modified site.
D.

The

product-ion

spectrum

of

the

180

triply

charged

molecular

ion

of

RLS*EEACPGVLSVAPTVTQPPGR originating from protein isoform 3 of A kinase
anchor protein 1, modified by heavy thiocholine at m/z 842.788 was obtained with an
ESI-LTQ-Orbitrap instrument as described in the Materials and Methods. “S*” indicates
the thiocholine-modified site.
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CHAPTER 5

Conclusions and Future Directions

In this dissertation, we demonstrate a novel strategy employing alkaline
β-elimination and Michael addition (BEMA) using natural abundance and stable isotope
labeled thiocholine in conjunction with mass spectrometry for specific detection,
identification and quantitation of phosphorylated serine/threonine containing peptides.
This strategy exploits the transformation of negatively charged phosphate groups to
endogenous positive charge bearing thiocholine moieties that resulted in a marked
increase in ionization sensitivity during ESI accompanied by enhanced peptide sequence
coverage during CID. The definitive localization of phosphorylated residues was greatly
improved through the generation of diagnostic triads of fragmentation ions resulting from
peptide bond cleavage and further neutral loss of either trimethylamine (-59 Da/-63 Da)
or thiocholine thiolate (-119 Da/-123 Da) from the thiocholine side chain during CID in
MS2 and MS3 experiments. The introduction of stable isotope labeled thiocholine enabled
the quantitation of protein phosphorylation with high precision by ratiometric
comparisons. The effectiveness of this developed technology was demonstrated in
proteins isolated from both a living cell system and a perfused tissue system undergoing
the pathologic alterations induced by myocardial ischemia. The endogenous
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phosphorylations sites of iPLA2β expressed in Sf-9 cells were identified. Comparison
with convention methods demonstrated superior results in both identification
phosphopeptides and localization of phosphosites. Moreover, quantitative analysis of the
mitochondrial phosphoproteome following cardiac ischemia was performed resulting in
the identification of 36 mitochondrial phosphopeptides with 37 new mitochondrial
phosphosites.
The effectiveness of the developed BEMA strategy relies heavily on the reduction
of sample complexity. In this thesis, a highly selective affinity enrichment resin, titanium
dioxide (TiO2), was utilized to eliminate the majority of the non-phosphorylated peptides
before conducting the BEMA reactions. This greatly increased the specificity of the
reactions and thus markedly improved reaction yields. Currently, a single reverse-phase
(RP) column was used to separate the peptides before mass spectrometry. A
two-dimensional (2-D) liquid chromatographic approach consisting of tandem strong
cation exchange (SCX) and reversed-phase (RP) columns can be employed to greatly
increase the sensitivity and the power of this approach [1-2].
Thiocholine possesses unique chemical properties that lead to the enhanced
ionization and generation of a rich repertoire of signature fragment ions upon CID. This
compound may also allow the affinity-purification of thiocholine containing peptides. It
has been previously reported that cavitand-based host molecules formed stable host-guest
complexes in water with quaternary amine containing small molecules [3]. The reversible
non-covalent binding between the aromatic pocket of the cavitand and the quaternary
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amine moiety of small targets is characterized by cation-pi interactions that have been
well defined [4-5]. Chemical fixation of the cavitand-based host molecules on a resin can
enable stationary phase extraction (SPE) of thiocholine-modified peptides for affinity
enrichment. The enrichment step could be either placed offline prior to the LC-MS
analysis or integrated as an additional dimension in the online HPLC separation.
As discussed in previous chapters, although the signature neutral loss of
trimethylamine and thiocholine thiolate were incorporated in the MASCOT search engine,
ions generated from neutral loss were not accounted for additional increase of
probability/confidence levels for identification of the peptides in this study. The
developed method is well-suited to be used with a weighted scoring algorithm that takes
into account the intrinsic chemical properties of thiocholine-containing peptides that will
likely enhance identification of phosphorylated peptides and phosphosites. Also the
anticipated development of bioinformatics resulting from this approach will increase the
utility of the current strategy. For example, a target MS3 template can be added to the
current options for the specific fragmentation of theoretical b and y ions instead of
fragmenting ions based solely on their relative intensity in product-ion spectra. An
automated quantitation program proceeding the validation of the peptide identification
also would greatly improve the efficiency of the current strategy.
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Appendix

A. 1H NMR (D2O) spectrum of natural abundance thiocholine

Figure A.
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B. 1H NMR (D2O) spectrum of thiocholine-13C,d3

Figure B.
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C. The scheme of the electron-donating effect of the β-methyl group of threonine
affecting the reaction rates of β-elimination and Michael addition

Figure C.
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D. Nomenclature of peptide fragment ions

Figure D.
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